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ABSTRACT 
Background 
Prosthetic heart valves do not fulfil the requirements for an ideal valve, resulting in 
the development of prosthetic dysfunction or complications over time.  Structural 
valve dysfunction may be influenced by multiple components which include 
patient’s factors, valve related factors and intraoperative factors. The inter-relation 
of these factors has a significant impact on morbidity and mortality associated with 
reoperative surgery for prosthetic valve dysfunction, particularly in a developing 
world where a large burden of communicable diseases together with lack of health 
care resources affect surgical outcome. In this study we examined the clinical 
records of the patients who underwent reoperative valve surgery to evaluate the 
clinical profile and factors that affect the surgical outcome after reoperation at a 
large tertiary referral center in a developing country. 
 
Objectives  
1) To describe the demographic profile of patients with malfunctioning 
prosthetic heart valves and define their clinical presentation 
2) To describe the clinical presentation of valve dysfunction  
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3) To determine the possible mechanisms of mechanical and bioprosthetic valve 
failure 
4) To determine the factors affecting the immediate surgical outcomes in 
subjects undergoing redo cardiac prosthetic valve surgery. 
 
 
Materials and methods 
A retrospective analysis of the clinical, perioperative and follow-up data of patients 
who underwent redo cardiac valve surgery for structural valve dysfunction between 
January 2005 and December 2014 at Inkosi Albert Luthuli Central Hospital, Durban, 
South Africa was undertaken. Patients were identified using the Speedminer 
software program which is a Data Warehouse software package used to store data 
collected on the hospital Medicom database. The file of each of patient who 
underwent redo cardiac prosthetic valve replacement for structural valve 
dysfunction was accessed and data were extracted on age, gender, potential risk 
factors for valve thrombosis, symptomatology, investigations including International 
normalized Ratio (INR) status and follow up. All patients were evaluated 
preoperatively by the cardiologist and the cardiothoracic surgical team and 
submitted for either an elective or emergency valve replacement. Excluded from the 
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study were those patients who underwent cardiothoracic surgery for nonvalvular 
reasons, i.e. coronary artery bypass surgery and congenital heart disease.  
 
Results 
 
During the ten year period (2005 to 2014) 2618 valve replacement operations were 
performed.  During the same period 128 reoperations (4.9%) were performed in 113 
patients (mean age 35.59 (SD±16.66) years). The majority of the patients were 
Black (72.6%) and female (75%). Fifteen patients (13.3%) were HIV infected and nine 
were pregnant. 
Acute dyspnoea (NYHA class III 34.37% and class IV 21.88%) was the presenting 
feature in 72 patients (56.25%). Clinical presenting features of an obstructed valve 
(flash pulmonary oedema with or without clinically audible prosthetic valve clicks) 
were documented in the clinical records of 44 of the 128 (34.4%) reoperations. In 
seventeen instances subjects presented with acute onset of cardiac failure (13.3%) 
and in eleven the presentation was characterised by signs of low cardiac output 
state (5.3%). There were no clinical indicators of an obstructed valve in the 
remaining 56 (43.8%). Of these 56 patients: 38 presented with change in effort 
tolerance and 18 where asymptomatic.  
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Valve dysfunction was detected by echocardiography and confirmed fluoroscopically 
in 71/128 cases (55.47%). In the remaining patients the diagnosis was made either 
at fluoroscopy (11.72%) or on echocardiography (32.81%). The ejection fraction (EF) 
was severely impaired (EF<40%) in 7.08% of patients. The mean left atrial size was 
52.28mm and mean pulmonary systolic pressure 45mmHg (range 26-104). 
 
Mechanical valve dysfunction was documented in 110/128 reoperations (obstructed 
valve (100) and prosthetic infective endocarditis (10). In almost two thirds of 
instances with obstructed mechanical prostheses levels of anticoagulation achieved 
were poor (INR<2.0); 30/110 (27.27%) were within therapeutic ranges of 2-4 and 
9/110 (8.18%) was >4.0. HIV status did not influence the outcome of surgery and 
did not appear to be the main mechanism of valve obstruction. The bioprosthetic 
valve group comprised the remaining 18 of 128 reoperations. In this group 13/18 
patients had structural valve deterioration with periprosthetic leaks, and remaining 
5 had prosthetic infective endocarditis (aortic root abscess (1) and annular 
dehiscence (4).  
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Emergency surgery was performed in 54.7% of the study population, of which 60.2% 
were in the mitral position. There was a total of 13 early in-hospital deaths (11.5%) 
of which one “on table” death was due to a low cardiac output state (LCOS). 
Postoperative mortality was related to prosthetic endocarditis (5/13) and high grade 
dyspnoea at presentation (7/13).  Multivariate analysis revealed that bypass time 
>3.5 hours (HR 5.58, 95%CI 1.24-24.95), cross clamp time >120 minutes (HR 4.48, 
95%CI 1.25-18.73), and third time redo operations (HR 4.26, 95%CI 1.23-14.75) 
were the independent predictors for early in-hospital mortality.  
 
Conclusion 
Our study shows a 4.9% reoperation rate after the previous valve replacement 
surgery with 11.5% perioperative mortality. Our results confirm that reoperative 
surgery is associated with significant morbidity and mortality.  More than half the 
patients presented acutely for mechanical valve obstruction which was due to 
inadequate levels of anticoagulation and required emergency surgery. Early 
mortality was related to poor NYHA class at presentation and to the presence of 
infective endocarditis. An important finding of this study was the high rate of valve 
obstruction associated with poor anticoagulation in patients who received the 
Cryolife On–X valve. They had a shorter interval to valve obstruction requiring redo 
valve replacement compared to the other mechanical prostheses.  
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Chapter 1:  Introduction 
Acquired cardiac valvular disease  
Acquired valvular disease affects different populations in the context of a country’s 
development and may be subdivided into rheumatic, degenerative and post 
traumatic causes.(1-3) Whereas degenerative heart disease is common in the 
western world rheumatic heart disease is still the predominant reason for heart 
valve surgery and prosthesis implantation in the developing countries.  Rheumatic 
valve disease has almost completely been eradicated in the industrialized countries 
due to the improvement of medical treatment, access to medical care and socio-
economic status.(2) The disease is only limited to the population of immigrants 
from developing countries but the most common heart valve entity in the developed 
world is degenerative valvular disease, as there is an increase in life expectancy in 
the developed world due to multi-factorial reasons. In our context, degenerative 
valve disease is observed in the Caucasian and Asiatic populations with better 
socio-economic status, lifestyle in urbanization and increased life expectancy.(3) 
 
Rheumatic valvular disease  
Rheumatic valvular disease remains a challenge in the developing world due to 
inadequate access to health care due to poor infrastructure in the health system, 
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vast rural areas with a large catchment area per primary health care clinic; 
furthermore, inadequate funding for basic medicines and a large burden of 
communicable diseases which determine preferential policy directives from the 
Department of Health that exclude rheumatic fever and heart valvular diseases. 
Although the incidence of rheumatic valvular disease has been on a downward trend 
throughout the developing world, it is still a major contributing factor for heart 
valve disease in children and young adults requiring repeated hospital admissions, 
which result in valve replacement.(2, 3) Rheumatic heart disease (RHD) results from 
untreated complications of rheumatic fever, which is commonly associated with 
group-A streptococcal infection during childhood. The antibodies form against the 
initial infection and cross-react with proteins in the heart valve creating an 
autoimmune reaction. The inflammatory responses from the autoimmune reaction 
lead to destruction of the heart valves. Nine to thirty-nine percent of patients who 
contract acute rheumatic fever develop associated valve deficiency two to ten years 
after the initial febrile episode, creating a bimodal age distribution with peaks in 
late childhood and early adulthood. Twenty percent of patients with RHD will die 
before the age of five, and eighty percent before they reach 25 years old. One of the 
most common long term manifestations of RHD is chronic valve deformity, 
occurring in twenty-five to forty percent of chronic RHD patients, many of whom 
require valve surgery when the disease is severe.(4-6)   
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Emerging valve disease and the influence of HIV infection 
There are new forms of heart valve disease that have emerged over the last 20 
years. The three main sources of these emerging valve diseases are 1) new 
infectious diseases such as HIV infection 2) drug-related diseases resulting from 
specific drug effects on a particular valve which has only been observed in the 
developed world and 3) new types of idiopathic disease (e.g. antiphospholipid 
syndrome).(2) In our setting, the epidemic of HIV infection has been associated with 
concomitant heart disease. Although HIV is not a direct cause of the heart valve 
disease, the immunocompromised state may be predisposed to systemic infection 
that subsequently results in an infective endocarditis. (2) Furthermore, a significant 
number of subjects who were receiving highly active antiretroviral therapy (HAART) 
with early generation drugs (e.g. stavudine) may develop the complication of 
lipodystrophic syndrome and atherosclerotic heart disease leading to degenerative 
valvular diseases.(7-10)  
The presence of concomitant retroviral disease has resulted in challenges in the 
management of valve disease, many of whom with advanced heart disease present 
for surgery. The true incidence of combined retroviral and heart disease in Southern 
Africa has not been well studied. The Heart of Soweto study shared some 
information about the spectrum of heart disease and risk factors in a black urban 
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population in South Africa. This study identified 1593/4162 subjects with newly 
diagnosed cardiovascular disease over a one year period (Jan-Dec 2006). Overall 
retroviral disease was identified in 74/1593 (5%). No data was given on cardiac 
complications related to HIV infection such as tuberculous-related pericardial 
disease and left ventricular dysfunction related to HIV infection. (11) Retroviral 
disease in valve disease category comprised 4%.   
Our study was conducted in the eThekwini municipality of the province of KwaZulu-
Natal (KZN), which is one of the nine provinces in the Republic of South Africa with a 
total land surface area of 94361 square kilometres and a population of 10.26 
million people. The population of KZN is composed of black African (86.6%), Indian 
or Asian (7.4%), Caucasian (4.2%) and Mixed Ancestry (1.4%). The Province of KZN is 
currently facing a large communicable disease burden in combination with a high 
rate of retroviral disease. The prevalence of HIV infection is highest (59%)  in the 
age group older than 24 years with a lower prevalence in the age group of 30-34 
years.(11, 12) It is therefore not surprising that many patients with chronic RHD 
have concomitant HIV infection.  This province is managing the largest Anti-
Retroviral Treatment program (ART) in the country, with the number of patients on 
ART increasing exponentially from 408238 (2010/2011) to 840738 (2012/2014).   
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The need for valve replacement surgery  
Of all the valve diseases that require intervention in our context, the majority are 
due to long standing chronic rheumatic valve disease while degenerative aortic 
valve disease accounts for the remaining few requiring surgeries. Regardless of the 
aetiology, long standing valve disease results in several pathophysiological sequelae 
that affect the functioning of the cardiac chambers. In brief, left-sided valve disease 
will have an impact on the function of the left atrium and the left ventricle. Stenotic 
mitral valve lesions create a pressure overload in the left atrium with resultant 
pulmonary hypertension and right ventricular dysfunction/failure while aortic 
stenosis imposes a pressure load on the left atrium and the left ventricle. In 
contrast, regurgitant lesions create a volume overload in the atrium and ventricle. 
Severe valve disease impairs effort tolerance, has an impact on quality of life and 
life expectancy. Left untreated it results in irreversible ventricular dysfunction, 
making it crucial to identify and treat the disease early with an appropriate timing 
for valve replacement surgery when the native valve disease become severe. A 
serious challenge with valve replacement surgery is the potential need for 
reoperation in the future due to prosthetic valve dysfunction. The decision to 
replace a native heart valve therefore requires a consideration of several factors, 
including the site and type of valve to be inserted, adherence to a strict 
16 
 
anticoagulation protocol, as well as an understanding of the ideal characteristics of 
the artificial prosthetic replacement valve.  
 
The Ideal cardiac prosthesis 
Since the artificial prosthetic valve is a foreign material inserted into the cardiac 
chamber and blood is constantly interacting with the prosthetic interface with the 
potential for thrombus formation, reduction of trauma of blood as it passes through 
the prosthetic material is crucial. The ideal valve is characterised by high durability 
since it has to function at 40 million cycles per year with minimal turbulence in the 
central orifice, and its internal design has to be such that the washout jet prevents 
thrombus formation over the hinge mechanism of the prosthetic valve.  
 
Advantage and disadvantage of each type of prosthesis 
Prosthetic valves may be classified into mechanical or biological, based on the 
composition of the valve leaflets. The major difference between them is the need 
for anticoagulation: biological (tissue) valves have properties that are similar to the 
human heart valve and therefore long term anticoagulation is not indicated when a 
biological valve is inserted at surgery but a drawback of the tissue valve is its 
limited durability. In contrast, the major drawback of the mechanical valve is the 
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mandatory need for anticoagulation therapy to prevent blood clotting and 
prosthetic valve thrombosis. Anticoagulation calls for frequent regular monitoring 
of blood coagulant activity (international normalised ratio (INR)) at a health facility 
to ensure adequate levels of anticoagulation without increasing the risk of bleeding, 
all of which affect the individual’s lifestyle and have an impact on quality of life 
after valve surgery.  
 
 
Figure 1. Different type of mechanical valves. A. Hufnagel design; B. Starr-Edward caged-ball design; C. Medtronic 
Hall single tilting disc design; D. St. Jude mechanical bi-leaflet design; E. Carbomedics Carbo-seal Valsava design. 
 
Mechanical prosthesis (Figure1) 
The evolution of mechanical heart valves started with the Starr-Edwards ball-and-
cage valve in 1962 and led to the development of the Kay-Shirley caged-disc valve 
in 1965.  Significant improvement in the design of the valve was made in the early 
1970s with single tilting-disc valve and this was followed by the St. Jude Medical bi-
leaflet mechanical heart valve in the late 70s which became the gold standard for 
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the most of its peers.  Although there are several mechanical valves with different 
profiles, no ideal mechanical prosthesis has been designed to date. The bi-leaflet, 
mono-leaflet and the ball-and-cage valves (Fig. 1B-D) have stood the test of the 
time as they have proven to be functional prostheses.  
 
Modern mechanical valves have several advantages in design: they have a lower 
profile and provide a larger effective valve orifice. They are associated with less 
structural deterioration in the younger population and have a longer life span.(13, 
14) The pyrolytic carbon discovered in late 1960s was found to be most suitable 
material for the mechanical heart valve because of its superior biocompatibility, 
resistance to wear and tear and lower thrombogenicity. The pyrolytic carbon or 
titanium-coated pyrolytic carbon composition of the leaflets provides better 
longevity compared to the earlier polycrystalline type of metal used as it is less 
prone to impact and fraction tear with subsequent fatigue failure.(13, 15) 
The bi-leaflet valve is thought to have less thrombogenicity and trauma to the 
blood with good haemodynamic flow through the artificial orifice. There have been 
numerous other attempts to improve the bi-leaflet design, which has resulted in 
various bi-leaflet mechanical valves in the current market. (1, 13, 15) 
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Biological prosthesis (Figure 2) 
The biological valve is derived from either bovine or porcine tissue; its life span 
after implantation has improved with the newer generation of valve preservation 
techniques. Biological valves may be mounted on a stent (Figure 2. A and B) or 
inserted without a stent (Fig 2 C).(16) Biological valves are implanted in older 
patients and/or in patients where anticoagulation is contraindicated; they have 
resulted in a reasonable outcome with a lower mortality. Biological valves are not 
implanted in patients who are considered unsuitable for open heart surgery. In such 
patients, transcatheter aortic valve implantation (TAVI), a percutaneous catheter-
deployed biological valve is indicated. This procedure has gained popularity 
particularly in the developed world where there is a growing population of 
septuagenarians and octogenarians. 
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Figure 2 The different types of biological cardiac prosthetic valves. A. stented porcine valve (Medtronic mosaic); B. 
stented bovine pericardial valve (Carpentier-Edwards Magna); C. Stentless porcine bio-prosthetic valve (Medtronic 
Freestyle); D. percutaneous bioprosthesis expanded over a balloon (Edwards Sapien); E. percutaneous self-
expandable percutaneous bioprosthesis (CoreValve). 
Choice of biological vs mechanical valve implantation 
There are multiple factors influencing the cardiac surgeon’s decision to implant a 
particular type of valve prosthesis, among them being the need for anticoagulation 
and the potential risk of complications thereafter. The surgeon takes into 
consideration several patient factors such as age, life expectancy, patient 
preference, the indications and contraindications for anticoagulation therapy, 
comorbidities and lastly access to a health care facility where patient’s INR may be 
monitored and adjusted in necessary.  Although the American College of 
Cardiology/ American Heart Association and European College of Cardiology have 
published guidelines on anticoagulation for prosthetic valves these 
recommendations can only serve as a guide in developing countries where 
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anticoagulation poses a major challenge because of difficulty in access to a health 
care facility for INR monitoring with a potential risk for thrombosed mechanical 
prostheses leading to  catastrophic consequence for the patient.(17-19)  
 
A brief guideline for the choice of mechanical prosthesis is based on the following 
considerations:  
1) The informed patient wants a mechanical valve with no contraindication for 
long term anticoagulation. 
2) The patient is already on long term anticoagulation for a previous mechanical 
prosthesis implantation, cardiac rhythm abnormality and high risk of 
thromboembolisation. 
3) The patient is at risk of rapid biological valve structural deterioration (young 
age, hyperparathyroidism and renal failure) 
4) The patient is younger than 65 years of age with a good life expectancy  
5) Easy access to local health facilities where the INR can be monitored and 
adjusted accordingly (critical factor for developing countries) 
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The choice of a biological valve selection is based on the following factors: 
1) The informed patient wants a biological cardiac valve 
2) Good quality of anticoagulation is not available (contraindications, high risk 
of bleeding, compliance issue, lifestyle factors, and poor or no access to a 
health care facility in the rural region.) 
3) The patient is older than 65 years of age with limited life expectancy 
4) The female patient is in child-bearing age. Biological heart valves tend to 
undergo rapid structural deterioration in this younger, child bearing age 
group for which they may return for redo valve surgery within a short space 
of time. 
 
 
Aetiology of prosthetic valve failure 
- Biological valve failure 
After implantation, the conventional stented bioprosthesis has a failure rate of 10-
30% in the first 10 years and 20-50% at 15 years.(13) Certain host and valve related 
factors may influence the rate of biological valve deterioration:  
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1) Host-related factors 
The age of the patient at the time of implantation has a strong influence of the 
rate of the biological valve deterioration; early failure usually occurs in the 
younger age group under 40 years of age (20-30%) and to a lesser degree in the 
in older age over 70 years of age (<10%).(13, 17, 18, 20-22)  Structural 
deterioration is more frequent in the mitral position because of exposure to high 
mechanical stress during systole. Structural deterioration of the aortic valve is 
more common in subjects with systemic hypertension because of the chronic 
elevation in the diastolic pressure. Pibarot and colleagues had described three 
pathophysiological mechanisms that contribute to bioprosthetic valve 
degeneration. Degenerative, immune and atherosclerotic processes act in 
concert to cause valve deterioration over time. (Fig.3) 
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Figure 3.  Possible mechanism for structural deterioration of the bio-prosthetic valve. Adapted from Pibarot P and 
Dumesnil JG. Circulation 2009.(13) 
 
. 
2) Valve-related factors 
Early generation biological valves used formaldehyde for fixation that resulted in 
early degeneration of bioprosthesis several years after implantation. This 
preservation technique employs chemical crosslinking to diminish the antigenicity 
of the xenogenic material (calf pericardial tissue) to further improve its stability and 
prevent autolysis. The disadvantage of glutaraldehyde fixation is that it 
decellularizes the valve and causes calcium influx which interacts with phosphorus 
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in the cell membrane to cause calcium phosphate crystal deposits. This is one of 
many reasons accounting for biological valve dysfunction and failure. In contrast, 
the new generation biological valve has undergone a chemical treatment at very low 
pressure, with surfactant and heat treatments, as well as modification of the stent 
design to decrease the rate of biological prosthesis deterioration and 
dysfunction.(13, 16, 21) 
 
- Mechanical valve failure 
Current problems associated with mechanical valves are the following: 
1) Structural dysfunction 
The repetitive cardiac cycle may cause fatigue to the valve material that 
subsequently leads to fracture of the valve leaflets.(15)    
2) Valve thrombosis and embolism 
The opening and closing of the mechanical prosthesis cause stasis and 
turbulence of the blood flow at the region of the implantation, which leads to 
platelets activation and thrombus formation. The common region of 
thrombus formation is the hinge mechanism where high shear stress and 
varying frequency of contact contribute to activation of platelets and 
26 
 
stagnation of blood flow. Blood clots may form at this point, enlarge and 
embolize to the peripheral organs.(15) 
3) Pannus formation 
Once the mechanical prosthesis has been implanted the human body will 
continue to epithelialize the sewing ring which is direct contact with the 
native valve annular tissue. This process varies with time, and as fibrosis 
builds up in the sewing ring it may result in overgrowth of fibrosis from the 
native annulus into the orifice of the mechanical valve. This causes 
turbulence in the blood flow and activates the clotting cascade, a process 
that contributes to leaflet dysfunction and obstruction. (Fig 4)  
4) Bleeding and haemorrhage  
The efficacy of anticoagulation with the coumarin anticoagulant warfarin, is 
monitored by measuring the INR level which requires a monthly blood 
sample to be taken at a health care facility and warfarin dose to be adjusted 
by the health care practitioner. The absorption and metabolism of this drug 
is influenced by several factors, particularly liver function, diet, concomitant 
drug usage and alcohol intake, all of which have an effect of the level of INR, 
resulting in a narrow index of safety. If the INR level falls too low then the 
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individual may prone to valve thrombosis, and if the INR is too prolonged it 
makes the individual more prone to bleeding upon minimal contact force. 
5) Endocarditis 
The mechanical valve has a sewing ring which made of Teflon, polyester or 
Dacron which serves as a nidus for bacterial colonization during any 
transient bacteraemia, leading to infection of the endocardium of the heart 
and predisposes to prosthetic valve endocarditis during episodes of 
bacteraemia. 
 
In summary, potential problems exist with implantation of an artificial heart valve, 
whether it is biological or mechanical. Host immune responses to foreign material 
implanted in the native valve position may cause the biological prosthesis to 
deteriorate with time, resulting in valve calcification and the eventual development 
of a stenotic lesion. The valve may become infected, resulting in leaflet perforation 
and leaflet destruction, or infection of the sewing ring leading to valve dehiscence 
and severe regurgitation.   
Problems with the mechanical prosthesis may result in stenosis or regurgitation. 
Structural failure or fracture, thrombus formation at the hinge mechanism or 
pannus ingrowth may result in a single leaflet becoming stuck in an open position, 
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or infective endocarditis may lead to periprosthetic valve dehiscence. All the above-
mentioned conditions may lead to a regurgitant lesion; thrombus formation at 
hinge mechanism or pannus ingrowth affect the hinge mechanism causing in one or 
both leaflets to become stuck in the closed/semi-closed position and a resultant 
stenotic ± regurgitant lesion. (Fig 4)  
 
Figure 4. Effect of prosthetic valve dysfunction on blood flow, the dynamics Numerical simulation showing the flow 
velocity distribution in bileaflet mechanical valves at a cardiac output of 5 L/min. A, Normally functioning bileaflet 
prosthesis. The flow velocity within the central orifice is higher than that in the lateral orifices. Accordingly, the 
peak gradient across the central orifice is 19 mm Hg, which is higher than the actual peak transprosthetic gradient 
(10 mm Hg). B, Mild prosthesis dysfunction with 25% restriction in the opening of 1 leaflet. The peak gradient is 20 
mm Hg. C, Severe prosthesis dysfunction with 1 leaflet blocked in the closed position. The peak gradient is 50 mm 
Hg. Courtesy of Drs Othman Smadi and Lyes Kadem, Concordia University, Montreal, Québec, Canada. Pibarot and 
Dumesnil Selection and Management of Prosthetic Valves 1039 
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Challenges associated with redo cardiac surgery 
After replacement, patients who develop prosthesis failure due to different 
aetiologies will require replacement of the underlying failed valve prosthesis (redo 
cardiac surgery). The redo heart valve replacement differs from the first-time 
surgery as the surgical outcome will be determined by several factors: 
1. The patient’s preoperative clinical condition and associated comorbidities. The 
most common presentation is a thrombosed mechanical valve which may result in 
the patient presenting in extremis in a shocked state, with low cardiac output state 
(LOCS) and multiple organ failure. 
2. The current status of left ventricular function which may or may not be affected 
by the intrinsic valvular prosthesis dysfunction. 
3. Any previous concomitant coronary artery bypass graft done and its patency. For 
instance, the left internal mammary graft to left anterior descending artery may lie 
behind the sternum. 
4. Closure of the pericardium from previous surgery. If the pericardium was not 
closed then enlargement of the right atrium due to the underlying valve prosthesis 
dysfunction exposes this chamber to potential injury upon chest re-entry.  
5. The presence of epicardial adhesions to pericardium that have resulted from 
previous surgery. Occasionally freeing the heart from previous cannulation sites 
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adhesion may result in injury to the great vessels or cardiac chambers and lead to 
massive haemorrhage. 
6. Time interval to cardiopulmonary bypass. The time taken to free the heart and 
place the patient onto the heart-lung machine for haemodynamic support may 
compromise ventricular function. 
 
Postoperative complications usually directly relate to patient’s preoperative profile 
(age, gender, preoperative clinical status and associated comorbidities); 
intraoperative techniques (pump time, aortic cross clamp time, type of cardioplegia 
used, amount of inotropic support and systemically induced corporeal cooling), all 
of which contribute to the patient’s postoperative state. 
 
In summary, valve surgery in the developing world present unique challenges 
related to the underlying disease aetiology and profile, as well as the choice of 
prosthetic valve for implantation. The effects of associated comorbidities such as 
HIV infection on blood coagulability and ventricular function may have an influence 
on outcome of valve replacement surgery.(23) The nature and design of prosthetic 
valves may account for structural valve dysfunction occur over time (usually 7-8 
years after implantation of the biological valve) while the major problem with 
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mechanical valves relate to the need for anticoagulation. Furthermore, surgical 
techniques become more challenging during redo cardiac valve surgery, which 
influence the operative surgical morbidity and predispose to postoperative 
complications and mortality. (24, 25)(Table 1) 
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Table 1. Complications associated with redo cardiac valve prosthetic surgery 
Possible complications associated with redo cardiac valve prosthetic surgery 
1. lower cardiac output state (LCOS) 
2. right ventricular failure and tricuspid regurgitation 
3. pulmonary hypertension 
4. thromboembolism (CVA)  
5. neurological disturbance 
6. renal failure 
7. arrhythmia and conduction abnormalities  
8. termination of pregnancy 
9. haemorrhage due to anticoagulation agent 
10. re-thrombosed valve  
11. prosthetic endocarditis 
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Chapter 2:  Overview and Literature Review 
Morbidity and mortality associated with cardiac valve reoperation 
Since the introduction of heart valve replacement surgery in 1960 (Dwight Harken) 
it has become clear that the benefits of valve surgery are not infrequently 
overshadowed by morbidity and mortality associated with anticoagulation and 
prosthetic valve thrombogenicity.  Despite advances in valve design that are 
associated with improved haemodynamics and less thrombogenicity, valve 
dysfunction remains a lifelong risk in these patients. Reoperation for the cardiac 
prosthetic dysfunction is associated with significant early mortality. Lytle and 
colleagues (27) documented 1000 consecutive redo cardiac valve surgery in 897 
patients from 1958 to 1984 at the Cleveland clinic, Ohio, USA. Their series had 
shown an overall early mortality at 12.1%. The early mortality for first operation for 
aortic and mitral valve was around 10% but increased to 14% with multiple valve 
reoperations and significant higher in tricuspid reoperation at 20%. There was a 
proportional increase in mortality with the number of reoperations. There was a 
high mortality for 3-5 reoperations in the aortic valve (33%), mitral valve (50%) and 
multiple valves (67%). (26) A larger series was published by Dr Piehler and co-
workers from three institutions over a thirty year period (1963 to 1992) (Mayo 
clinic, Birmingham Veterans Affairs Medical Center, St. Vincent Hospital and Medical 
Center and the Oregon Health Sciences University).(28) There were 2246 
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reoperations in 1984 patients (1395 Male and 851 female). The age ranges from 
1.5 to 88 years with mean of 52 years ± 16 years at the time of redo cardiac valve 
surgery. The unadjusted early mortality was 10.8%. The commonest cause of 
reoperation was a periprosthetic leak without evidence of infective endocarditis 
(600/2246), degeneration of bioprosthesis (558/2246), pannus ingrowth 
(121/2246) and device thrombosis (75/2246). (27) Other studies comprising a 
sample size over 100 patients undergoing redo cardiac valve surgery in the last 20 
years showed an early mortality between 4% (Luciani)(28) and 13.1% (Sener)(29). 
These data show a varying mortality rate for reoperative cardiac valve surgery 
across institutions. Factors that affected postoperative mortality included the 
patient’s preoperative clinical condition, intraoperative technical factors and 
postoperative intensive care unit management. 
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Series Study duration Patients Valve Position Valve Type Early Mortality (%) 
Lytle et al, 1986 (26) 1958–1984 897 AV, MV, TV B 12.1 
*Deviri et al, 1991 (30) 1980-1989 100 AV, MV M 12.3 
Bortolotti et al, 1994 (31) 1966–1992 549 AV, MV B 11 
Piehler et al, 1995 (27) 1963–1992 1984 AV, MV B 10.8 
Tyers et al, 1995 (32) 1975–1992 708 AV, MV, TV B 11 
Sener et al, 1995 (29) 1984–1993 154 AV, MV B 13.1 
Akins et al, 1998 (33) 1985–1997 400 AV, MV T 7.8 
Jamieson et al, 2003 (18) 1975–1999 463 MV T 7.1 
*Taljaard et al, 2003 (34) 1991-2001 32 AV, MV M 64.7 
Luciani et al, 2006 (28) 1997–2002 290 AV, MV B 4 
Tang et al, 2007 (35) 1997–2002 743 AV, MV, TV B 9.4 
*Current series 2005-2014 128 AV, MV, TV B 11.5 
 
Table 2. Results of reoperative valve surgery compared to South African studies* 
AV= aortic valve; MV= mitral valve; TV= tricuspid valve; B= both (tissue and mechanical); T= tissue; M= 
mechanical. 
An early mortality is defined as intraoperative death, and postoperative death (intensive care unit, high care and 
ward admission) within 30 days of the surgery. 
 
i. Prosthesis type and the Site of implantation 
Tang et al reviewed 743 patients who underwent mitral and /or aortic valve redo 
surgery in Toronto between 1990 to 2005. There were 236 mechanical and 507 
biological prostheses. Twenty percent of those with mechanical valves underwent 
urgent surgery compared to 12% with biological valves. Severe dyspnoea (NYHA III 
to IV) was the presenting feature in 87% with mechanical and 81% with biological 
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valves. The mechanical group was much younger and had less concomitant 
Coronary Artery Bypass Grafts (CABG) at the time of first valve replacement. 
Retroviral status was not described in the study population.(35) 
 
The site of valve implantation had some bearing on the rate of prosthetic valve 
deterioration. Tang et al. showed that 371 out of 507 biological valves explanted 
were in aortic position and 175 out of 507 were in mitral position.(35) The 
biological valve in the aortic position seemed to deteriorate more rapidly in the 
presence of systemic hypertension, LV hypertrophy, poor LV function and patient 
prosthetic mismatch. These conditions are associated with a high pressure gradient 
over the aortic valve leading to high diastolic closure stress over the biological 
leaflets predisposing to structural valve dysfunction (SVD). Persistent left ventricular 
hypertrophy after bioprosthetic aortic valve replacement also had a higher incidence 
of structural valve deterioration (SVD) requiring reoperation (HR 2.38 (95% CI 
1.61,3.51; P<0.001).(22) In contrast, causes of SVD in the mitral position were 
young age, renal failure and hyperparathyroidism.(13, 18, 21, 22) Similar findings 
were reported in the Veterans Affairs 15year randomized trial by Hammermeister et 
al who found a higher rate of reoperation for bioprosthetic aortic valve 
replacement.(36) 
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In another large study Ruel et al. studied 3233 subjects who had undergone 3856 
operations over 32 years duration in Ottawa, Canada. After excluding 291 (9.0%) 
who were lost to follow-up completely after valve replacement, and a further 350 
patients (10.8%) who were only lost to follow-up later with a mean of 4.7±4.3 years 
after valve replacement the group studied the remaining group of 2348 patients. 
Actual freedom from all-cause reoperation at 10, 15 and 20 years was 96.2, 94.1, 
and 93.8% for aortic mechanical valves and 96.4, 94.8, and 94.2% for mitral 
mechanical valves. Freedom from all-cause reoperation was 76.1, 61.4, and 59.6% 
for aortic bioprosthetic valves, and 79.8, 63.3, and 57.6% for mitral bio-prosthetic 
valves. The range of ages for the aortic and mitral valve reoperation were similar 
(48.3-75.5 aortic and 46.8-71.6 mitral). Redo surgery with valves implanted at the 
aortic and mitral position were described at the 20 years follow up: mechanical 
(6.2% in aortic vs 5.8% mitral) and biological prosthesis (42.4% in mitral vs 40.4% 
aortic). There was a higher rate of reoperation for the bioprosthetic valve group 
rather than mechanical valve group due to structural valve deterioration.(19) These 
authors showed that the site of valve implantation and the age of the patients did 
not affect the outcome of reoperation.  
 
Rizzoli et al. from Isituto Chirurgia Cardiovasculare, University of Padova, Italy, 
studied 755 patients who underwent 863 re-operations between 1st January 1970-
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1995. Operative age was 53.08 ±13.77 (range, 10 to 83 years). There were 289 
mechanical prostheses VS 60 biological in aortic position and 441mechanical VS 
164 biological in mitral position. The mitral position had a higher reoperation rate 
for both biological and mechanical prostheses groups.   
 
Bortolotti et al. from Isituto Chirurgia Cardiovasculare, University of Padova, Italy, 
studied 330 patients who underwent first reoperation of 351 bioprostheses which 
composed of 88 patients who underwent surgery in the aortic position, 221 mitral, 
21 mitral and aortic between 1970-1990. The primary indication was structural 
valve deterioration (87%), followed by periprosthetic leaks (7%) and endocarditis 
(6%). This group had a high reoperation rate in the mitral position compared to the 
aortic position for the bioprosthetic valves.(42) 
 
In another study Tyers et al. studied 708 reoperations out of 5499 previous primary 
valve operations over a 17 year period: 3.4% was redo for mechanical prostheses 
and 16% was redo for biological valve failure. The cumulative follow-up prior to 
mechanical prosthesis replacement was 105 patient-years (mean follow up 2.4 ± 
SD 2.2 years; range of 5 days to 7.3 years). In contrast, the follow–up for the 
biological valve implantation was 5,429 patient-years (mean follow up 8.2 years ± 
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SD 3.8 years; range 10 days to 18.3 years). In this study the mechanical valve was 
associated with early reoperation. This study did not provide the patients’ 
preoperative surgical condition which may have been a significant factor for 
postoperative morbidity and mortality.(32) 
 
ii. Mechanical valve reoperation: valve obstruction 
Possible factors that are associated with early mechanical valve reoperation and 
related complications are summarised in the studies discussed below. The most 
devastating complication, valve obstruction, is associated in the majority cases with 
a typical clinical presentation characterized by the acute onset of dyspnoea or 
pulmonary oedema with or without cardiogenic shock.(18, 25, 37-40) 
 
Two South African studies that have evaluated mechanical valve obstruction, have 
shown varying postoperative morbidity and mortality for reoperation.  Deviri et al. 
studied 100 patients presenting with mechanical valve obstructions over 9 years 
duration at Baragwanath Hospital, University of Witwatersrand and showed that 46 
presented with class III to IV dyspnoea (47.9%) and 24 with low cardiac output state 
and shock (25%). Eight patients were completely asymptomatic (8.3%). All patients 
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underwent urgent operation once the diagnosis of obstruction was made.(30) The 
early mortality rate was 12.3%. 
 
In the second study, a ten year evaluation of prosthetic valve obstruction at 
Tygerberg hospital between 1991 and 2001, Taljaard et al. showed that in 25 out of 
34 events the patients presented with class III to IV dyspnoea (74%): 91% were in 
pulmonary oedema and 26% had a low cardiac output state. In this study three 
patients were asymptomatic and one tested HIV positive. Emergency operation 
(within 24 hours) was performed in 50% of cases, while 42% underwent elective 
surgery.(34) The overall mortality was 64.7%. These studies showed that early 
surgical intervention was associated with a lower postoperative mortality rate. 
 
iii. Influence of native valve disease on prosthesis dysfunction  
To what extent the underlying preoperative native valve disease may contribute to 
future prosthetic valve dysfunction has not been studied. One reason is that 
younger subjects with rheumatic disease would receive a mechanical prosthesis due 
to its good life span while the older population with concomitant ischaemic 
coronary artery disease are likely to receive a biological prosthesis. (11, 14-16) 
Predisposing factors to thrombosis include the native valve position, the degree of 
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left ventricular dysfunction, the degree of the left atrial enlargement, and the 
presence of atrial fibrillation (AF). Systemic thromboembolism is much less common 
with aortic compared to mitral valve disease. It is usually associated with coexisting 
mitral valve disease and atrial fibrillation. It may be the presenting manifestation in 
more than 10% of the patients with mitral stenosis. The presence of AF increases 
the risk of systemic thromboembolism by 3-7 times (33-36), and even higher up to 
an 18-fold as estimated in the Framingham study. (37, 38) The incidence of 
systemic embolism is between 1-5% per year for mitral disease.(33, 34, 36, 39, 40)  
 
iv. Mechanical vs bioprosthesis and the influence of age 
The age of the patient when the biological valve is implanted is important since 
younger patients have a more active immune system which reacts to the residual 
animal antigen on the surface of the biological valve, leading to a humoral and 
cellular response. The response of various cellular compartments may release 
inflammatory cytokines and result in mineralization of the leaflets explaining why 
the biological prosthesis is prone to structural valve dysfunction (SVD) much faster 
in the young population.(13, 18, 37) The rate is between 20-30% in patients under 
40 years and under 10% in the elderly (>70yr). As the leaflets lose their flexibility 
they may become thickened, resulting in a stenotic lesion, or they be subject to 
tears which result in a regurgitant lesion.(13) 
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In the Veterans Administration outcome study 15 years after valve replacement 
Hammermeister et al. reported showed that the all-cause mortality after aortic valve 
replacement was 13% lower in the mechanical valve group compared to 
bioprosthetic group, but this finding was not demonstrated in the mitral position. 
Biological valve structural failure occurred more frequent under age 65years (aortic 
26% vs mitral 44%) compared to older subjects over 65years (aortic 9%: mitral 6%). 
The mechanical prosthesis across age groups showed no mechanical structural 
failure in both positions.(36)  
 
In their study on the determinants of reoperation Ruel et al. showed that the mean 
ages for aortic, mitral and double valve replacement were 61.9 ± 13.6, 59.2 ± 12.4, 
58.5±12.4 (P < 0.05), respectively; freedom from all-cause reoperation at 10, 15 
and 20 years was 96.2, 94.1 and 93.8% for aortic mechanical valves, and 76.1, 61.4 
and 59.6% for aortic bio-prosthetic valves. Similar data were reported for the mitral 
position: 96.4, 94.8 and 94.2% for mitral mechanical valves, and 79.8, 63.3 and 
57.6% for mitral bio-prosthetic valves. This study demonstrated that structural 
valve deterioration accounted for the much higher rate of reoperation in the 
bioprosthetic group.(22)  
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In contrast, recent studies have shown that improvements in the design of the 
mechanical prosthesis, the material used, and better flow dynamics have led to the 
construction of mechanical heart valves that are more durable, easily implantable 
and associated with less thrombogenicity. The incidence of valve dysfunction due to 
intrinsic structural dysfunction is reported to be rare with the newer generation bi-
leaflet mechanical valves.(13, 15) Whereas the early generation mechanical 
prosthesis had low but significant rate of stress or fatigue fracture this problem 
seems to be less in the newer generation more durable pyrolitic carbon leaflets. 
 
v. Valve size:  
In a report of 3014 valve operations performed from 1970-1997 Rizzoli et al. 
described 334 reoperations with 290 first operations, 27 second operations, 6 third 
operations and 1 fourth operation. This group showed that reoperations occurred in 
71 patients with an aortic prosthesis less than 21mm and in 184 patients with a 
mitral prosthesis less than 27mm: 39% of reoperations were for prosthetic valve 
dehiscence, 13% for pannus in-growth and 8% of valve thrombosis. (25) In their 
multivariate analysis of factors predisposing to prosthetic thrombosis they 
identified the mitral and tricuspid position as incremental risk factors. A novel 
finding was the protective effect of larger size of prosthesis greater than 27mm 
diameter; this could be explained by more regular transvalvular flow and reduction 
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in the risk of the thrombosis in the mitral prosthesis. Large prosthetic size 
(>27mm), Sorin tilting disk prosthesis and bileaflet prostheses were associated with 
67%, 69% and 83% risk reduction respectively. (24) 
Patient-prosthesis mismatch (PPM) has been identified as a factor that may 
predispose to structural valve deterioration of the biological valve and to 
thrombosis of the mechanical prosthesis. Jamieson et al. have shown that a lower 
freedom from reoperation was associated with a larger body surface area (Hazard 
ratio ((HR))1.84 per meter square increase in BSA).(19) Ruel and colleagues have 
shown that a larger bioprosthesis size in the aortic position was associated with an 
increased freedom from reoperation for structural valve deterioration (HR 0.82 per 
increase of one valve size independent of BSA)(23). They also showed that the ratio 
of prosthesis size/BSA below the 10th percentile valve of cohort studied was 
associated with HR 1.79. This relationship did not exist for the mitral bioprosthesis. 
They found that a higher patient-prosthesis mismatch in the aortic position 
resulted in more rapid structural valve deterioration of the bioprosthesis and 
necessitated earlier reoperative surgery. These data emphasize the importance of 
correct valve size at the first operation in preventing the sequelae associated with 
PPM.  
 
 
45 
 
vi. Blood stasis and systemic embolism 
Early studies have shown that a low cardiac output state prior to surgical 
replacement for native valve disease is an important risk factor for systemic 
embolism.(41-43) Also, poor contractility of the left ventricle with slower circulation 
within the cavity contributes to stasis of the blood flow, predisposing to thrombosis 
formation. This is commonly observed in the infarcted anterolateral and apical walls 
of the left ventricle which become hypokinetic or akinetic with resultant thrombus 
formation in the apical segment.  A similar mechanism is probably operative in 
patients with impaired left ventricular function who undergo mechanical prosthesis 
implantation. 
 
Left atrial size and AF are two of the major contributing factors to the systemic 
thrombus formation and commonly associated with a large atrium in the mitral 
valvular disease. The left atrial appendage is the most common site of the thrombus 
formation due to the abnormal rhythm causing the stasis of the blood in the most 
peripheral part of the atrium. Szekely et al. have shown that one third of emboli 
occurred in the first month and two thirds occurred within 12 months of onset of 
AF. The incidence increases with age. (43, 44) 
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vii. HIV status 
The effect of the Human Immunodeficiency Virus (HIV) in relation to the chronic 
inflammatory process and an increase in vascular thrombogenicity has recently 
been documented (41,42). Funderburg and Lederman et al. have shown that the HIV 
infected individuals have an increased risk of arterial and venous 
thromboembolism.  They found that HIV infected patients who are receiving HAART 
had 2 to 10 fold greater risk of developing venous thrombosis and 2 fold greater 
risk of developing myocardial infarction.(41,42) Although the exact aetiology has 
not been identified. It has been hypothesized that chronic inflammation triggers the 
coagulation pathway and increases the viscosity of blood in these patients. There is 
also some evidence that HIV disease may contribute to anticoagulation failure, a 
factor that may contribute to prosthesis dysfunction.  
 
Chong et al. evaluated the outcome of 22 patients with HIV infection who 
underwent primary cardiac valve replacement during 1990-1999. The mean age of 
the study population was 37.2 years with male dominance (15/22). Fifty percent 
(11/22) of the patient had mechanical valve, 7 had bioprostheses and 4 had 
homografts. Intravenous drug abuse was reported at 16/22 patients. Although they 
had a 94% survival at one month this reduced to 50% at 5 years. The poor late 
survival was due to progression of HIV disease and continuation of risk prone 
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behaviour.(23) This study did not document the treatment status of their patients 
and did not examine the mechanism of late death after valve replacement. 
 
The Department of Health (DOH) in KwaZulu-Natal, South Africa has already 
implemented its High Active Anti-Retroviral Disease Treatment (HAART) program 
since 2012. Although surgery may be carried out successfully in HIV infected 
subjects (23) the effect of HAART rolls out program after valve replacement is yet to 
be determined.  
 
Factors influencing surgical outcome of redo valve surgery 
i. Perioperative risk and mortality  
Early experiences have shown a high postoperative mortality rate in patients with 
obstructed mechanical prosthesis who present with the NYHA class IV symptoms. 
Improvements in medical technology, surgical techniques, anaesthesia and 
perioperative care as well as earlier detection of the thrombosed valve prostheses 
have had a significant impact on morbidity and improvement on the postoperative 
mortality.(37) 
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Locally, Deviri E and co-workers et al. have shown a mortality of 4% for patients 
with NYHA class I, II, III and a much higher mortality of 17.5% for patients 
presenting with NYHA class IV symptoms in 100 patients who underwent 106 valve 
replacements for obstructed mechanical cardiac prostheses at the University of 
Witwatersrand Hospital in Johannesburg between 1980 to 1989.(30) Taljaard and 
Doubell et al. also showed a very high mortality for patients presenting with NYHA 
class IV symptoms.  They studied 32 patients who presented in 34 occasions with 
prosthetic valve obstruction at Tygerberg hospital between 1991-2001.  Two thirds 
of their subjects presented with NYHA class IV symptoms and poor INR control and 
their operative outcome was poor with  a high overall mortality of 64.7%.(34) 
 
The rapidity of onset of valve dysfunction and perioperative risk factors also have a 
bearing on the outcome. Rizzoli et al. showed those subjects with prosthetic valve 
thrombosis who had severe perioperative risk factors had lower survival (49% at 30 
days and 18% at 17 years) compared to subjects who had pannus ingrowth into the 
prosthetic valve with high perioperative risk factors (94% at 30 days and 74% at 17 
years).(25) This can be explained by the acute haemodynamic instability associated 
with thrombosis of the mechanical prosthesis as opposed to a more insidious onset 
of leaflet malfunction due to pannus ingrowth that allows the left ventricle and the 
left atrium time to compensate for the change in haemodynamics.(31) 
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ii. Influence of LV function on outcome and survival  
LV dysfunction may be present from at the time of the first valve implantation and 
is related to duration of the underlying native valve lesion prior to surgical 
correction. To what extent this affects prosthetic valve function has not been fully 
established. Morishita et al. analysed the long term results and risk factors for long 
term survival rate after valve re-replacement for the prosthetic valve dysfunction in 
subjects under 70 years. Subjects with an EF < 0.39 at the time of surgery had 
lower survival rate (83-98% at 1yr and 31-56% 5 yrs) compared to those with EF> 
40% (96-98% at 1yr and 90-94% at 5yrs). This study identified higher NYHA class, 
male predominance and tricuspid regurgitation as factors that affected the hospital 
death and long term survival, while NYHA IV and lower left ventricular ejection were 
independent predictors of early in-hospital morbidity and mortality as well as long 
term survival.(31) 
 
In Morishita et al’s study 7 patients out of 107 with LV dysfunction had an EF that 
was less than 39%. This group had 83% one-year survival and a 5-year survival was 
31%, as compared to a 96% and 90% survival respectively in the group with normal 
ventricular function. In this study advanced NYHA and lower EF were independent 
predictors of late deaths, having a negative effect on the long term survival.(45)35 
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Similarly, Taljaard and Doubell et al. showed a high early mortality was associated 
with high NYHA class and LV dysfunction at Tygerberg hospital. Those patients who 
presented in cardiogenic shock had 100% mortality, and only 4 out of 25 patients 
who were severely symptomatic (NYHA III and IV) survived.(34) Of the 20 who died 4 
deaths occurred on the surgical table for emergency surgery and 11 had an early 
in-hospital mortality; Ten of the 11 patients who presented with NYHA class IV 
dyspnoea succumbed. Similarly, in Deviri et al’s study, 11 out of 63 patients (17.5%) 
who had  NYHA class IV symptoms and underwent emergency redo valve 
replacement surgery demised in the perioperative phase.(30) 
 
Rationale for this study  
Inkosi Albert Luthuli Central Hospital based in the province of KwaZulu-Natal serves 
a population with an unique set of circumstances with regard to socio-economic 
status, distribution of healthcare service, and the large burden of communicable 
and non-communicable disease. These factors may have a significant impact on 
patients undergoing valve surgery as well as the outcome of patients undergoing 
reoperations for valve dysfunction. Furthermore, the choice of mechanical and 
biological valves has changed recently based on availability and cost. The effects of 
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all these factors, including the retroviral status of subjects who are presented for 
cardiac valve replacement surgery have not been evaluated. What potential effect 
the retroviral status has on coagulability and valve function has not been studied. 
This study plans to assess the clinical profile and factors that determine the surgical 
outcome of those patients undergoing reoperation for prosthetic valve dysfunction. 
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Chapter 3:  Aims, Materials and Methods  
Aims 
To evaluate the pre, intra and postoperative data of all the patients who underwent 
redo valve replacement for cardiac prosthetic valve dysfunction.  
Hypothesis 
Re-operative valve surgery is associated with considerable morbidity and mortality.  
Objectives 
1. To describe the demographic profile and clinical presentation of patients 
with prosthetic valve dysfunction. 
2. To determine the possible mechanisms and aetiology of prosthetic valve 
dysfunction. 
3. To determine whether human immunodeficiency virus infection is associated 
with prosthetic valve dysfunction  
4. To determine the immediate surgical outcome and early in-hospital mortality 
at a large referral centre. 
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Materials and methods 
A retrospective analysis of the perioperative and follow-up data of patients who 
underwent redo cardiac valve replacement for structural valve dysfunction between 
January 2005 to December 2014 at Inkosi Albert Luthuli Central Hospital (IALCH), 
Durban, South Africa was undertaken. Excluded from the study were all subjects 
who underwent cardiothoracic surgery for nonvalvular reasons, i.e. coronary artery 
bypass surgery. Patients were identified using the Speedminer software program. 
Speedminer is a Data Warehouse and Business Performance Management software 
package, used by IALCH since 2006 to manage, process and categorise the data 
collected on its Medicom database. The file of each of patient who underwent redo 
cardiac prosthetic valve replacement for structural valve dysfunction was accessed 
and data were extracted on age, gender, potential risk factors for valve thrombosis, 
symptomatology, investigations including INR status as well as follow up decisions. 
Investigations were recorded together with subsequent admissions and reviewed 
diagnoses during follow up. 
 
The study group comprised all those who underwent redo valve surgery for 
structural mechanical and biological valve dysfunction. Valve dysfunction requiring 
surgery was defined as any impairment in valve function leading to prosthetic valve 
stenosis/blockage or regurgitation. Patients referred from a peripheral hospital with 
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suspected valve dysfunction (history of previous heart valve replacement and the 
clinical features of cardiac failure, dyspnoea, haemoptysis, pulmonary oedema and 
a low cardiac output state) were evaluated by the cardiologist at IALCH and valve 
dysfunction confirmed on transthoracic echocardiography and/or fluoroscopic 
screening. The clinical presentation, transthoracic echocardiogram, fluoroscopic 
screening and blood investigations were reviewed by the cardiologist and 
cardiothoracic surgeon prior to surgery. 
 
Surgical Procedures 
Surgery was performed via a sternal re-entry with division of retrosternal 
mediastinal adhesions to expose the pericardium and free the heart from adhesions 
due to previous surgery. Cardio-pulmonary bypass was instituted and systemic 
hypothermia induced with cardioplegic arrest using blood or crystalloid solution 
employed for myocardial protection. Once the heart was mobilised the 
dysfunctional prosthesis was explanted with preservation of the annulus, and tissue 
submitted for culture to guide antibiotic therapy in suspected infective endocarditis. 
The size of the annulus was measured and the new valve implanted with pledgeted 
Ethibond sutures. The patient’s presenting condition, duration of cardiopulmonary 
bypass and cross clamp time, as well as the postoperative use of inotropic support 
were recorded as potential contributors to postoperative morbidity and mortality. 
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Immediate outcome was analysed by evaluating data in the first 30 days for 
postoperative morbidity and mortality, and thereafter at the 6 weeks and six month 
follow-up visits postoperatively. Left ventricular function as assessed by ejection 
fraction and cardiac chambers were compared pre and postoperatively to determine 
whether any change in ventricular function correlated with clinical symptomatology 
and outcome. 
 
Statistical analysis 
Statistical Package for the Social Sciences (SPSS version 18.0) was used for analysis 
of data and a 95% level of confidence estimated; a global significance level of ά = 
5% was chosen.  
Descriptive statistics (expressed as the mean +/- standard deviation) were used for 
the following parameters: age, gender, functional class of dyspnoea, comorbidities, 
previous native valve disease, previous prosthesis implanted, duration between 
previous surgery to the redo prosthesis replacement, transthoracic echocardiogram 
parameters (ejection fraction, end diastolic dimension, end systolic dimension, size 
of left atrium and aortic root, pulmonary systolic pressure) and blood biochemistry ( 
pre-op INR, full blood count and serum electrolytes).  
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Odds ratios were calculated to evaluate the strength of associations between the 
demographics, clinical presentation, risk factors and valve dysfunction. The chi-
squared and Fishers exact test was used to compare categorical variables and the 
Student’s unpaired t-test was used for continuous variables, to assess the 
significance of any difference in risk between the two groups (those with 
mechanical and biological valves). A p-value <0.05 was regarded as significant. 
Binary logistic regression analysis was used to control for confounding factors when 
assessing the independent relationships between risk factors for valve thrombosis 
and the outcome variable (valve dysfunction).  Multivariate analysis was used to 
assess the effect of clinical criteria and other risk factors on the likelihood of 
prosthetic malfunction.  Actuarial survival curves were calculated by the Kaplan-
Meier failure estimate method, and the log-rank test was used to compare 
subgroups. A p-Value of less than 0.05 was considered significant. 
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Chapter 4: Results 
Number of Valve replacements  
During the ten-year period (2005 to 2014) 2618 valve replacement operations were 
performed and 2618 valves implanted into aortic, mitral and tricuspid positions. 
(Table 2) There were 165 biological valves implanted and the remainder were 
mechanical valves as follows: Cryolife On-X 2151, Medtronic Mechanical 177 
(Advantage 150, ATS 27), Saint Jude 124 and Carbomedics Sorin 1. A total of 128 
reoperations (4.9% of 2618 replacement operation) were performed in 113 patients 
during this period with an average number of 12.8 reoperations per year. The 
highest number of reoperations (22) were performed in 2014. Of the 128 
reoperations 94 (73.43%) had one reoperation; 23 patients had two; 9 patients had 
three and 2 had four operations during the ten year period. 
Table 3. Valve replacement surgery during 2005-2014 
 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 
MVR* 124 148 113 127 116 85 119 114 97 94 
AVR* 31 36 31 24 31 29 38 55 46 44 
TVR* 0 0 0 0 1 0 0 0 0 2 
DVR* 38 49 58 57 36 44 44 44 47 57 
OMV* 0 0 1 0 0 0 0 0 0 0 
Tricuspid valve 
replacement 
0 0 1 0 0 1 0 0 0 1 
CABG+MVR* 5 8 8 5 5 4 5 4 1 2 
CABG+AVR* 1 8 5 6 5 2 9 10 6 7 
CABG+DVR* 1 1 1 2 0 2 1 0 0 0 
Modified Bentall 1 3 5 3 3 3 6 4 2 4 
operations  
valves implanted 
201 
240 
253 
303 
223 
281 
226 
283 
199 
235 
172 
216 
223 
267 
231 
275 
199 
246 
215 
272 
reoperations  14 15 9 15 7 8 13 18 7 22 
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* Abbreviation for table 2: MVR=Mitral Valve Replacement, AVR=Aortic Valve Replacement, DVR=Double Valve 
Replacement (AVR+MVR), TVR=Triple Valve Replacement (AVR+MVR+Tricuspid Valve replacement), 
OMV=Open Mitral Valvotomy, CABG=Coronary Artery Bypass Grafts. 
 
Demographic data and premorbid disease profile  
 
The demographic data of the 113 patients at the time of first presentation for 
reoperation at IALCH are shown in table 5. The most frequent premorbid native 
valve morphology prior to the first valve operation was mitral valve disease (62.5%), 
followed by left-sided double valve disease (23.44%) and aortic valve disease 
(11.72%) (table 4). Over a quarter (26.19%) had redo surgery within 2 years of 
previous valve surgery, with the remaining patients presenting at variable periods 
thereafter.  
Table 4: Premorbid native valve disease and previous surgery  
Previous native valvular disease Reop=128 % 
Aortic stenosis (AS) (SAM) 9 7.03 
Aortic regurgitation (AR)(sinus of Valsalva) 8 6.25 
Mitral stenosis (MS) 39 30.47 
Mitral regurgitation (MR)(+ASD) 41 32.03 
Double valve disease (Aortic + Mitral) 30 23.44 
Tricuspid regurgitation 
 
1 0.78 
Interval between previous and current operation   
0-2 years 
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26.19 
 
2-10 years 59 38.89 
>10 years 44 34.92 
 
The overall mean age at reoperation was 35.59 (SD±16.66) years with the 64.6% of 
the patients being under the age of 40 years (table 5). The median age for the 
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mechanical valve group was 30 years (mean 31.4, 95% CI 28.7-34) and the median 
for biological group was 54 years (mean 52.8, 95% CI 44.9-60.6). Most reoperations 
were performed in Black African subjects (72.6%) and three quarters of the subjects 
were female. Fifteen subjects (13.3%) were HIV infected and all received mechanical 
prosthetic valves: thirteen subjects were female and two were male. Anticoagulation 
was poorly maintained (INR<2) in 61.81% of patients.  
Table 5. Demographic data  
Characteristic  n=113 % 
Age   
   <=18 20 17.7 
   19-30 29 25.7 
   31-40 24 21.2 
   41-50 14 12.4 
   >50 26  23 
Race   
   Black  82 72.6 
   Mixed Ancestry  3 2.6 
   Indian  19 16.8 
   Caucasian 9 8.0 
Gender   
   Female 74 65.5 
   Male 39 34% 
HIV status    
   Negative 98 86.7 
   Positive 15 13.3 
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Clinical presentation at reoperation 
 
High grade dyspnoea was the presenting feature in 72 subjects (56.24%) (Table 6): 
34.37% were NYHA class III and 20.31% class IV. Two subjects (1.56%) arrived at the 
referral hospital intubated. Low grade dyspnoea (NYHA class I and II) was present in 
56 out of 128 (43.75%) subjects.  Ninety-eight subjects (76.6%) were in sinus 
rhythm, most of the remainder (18.6%) being in AF. 
Clinical presenting features of an obstructed valve (flash pulmonary oedema with or 
without clinically audible prosthetic valve clicks) were found in the clinical records 
of 44 of the 128 (34.4%) reoperations. In seventeen instances subjects presented 
with acute onset of cardiac failure and in eleven the presentation was characterised 
by signs of low cardiac output state: syncope and pre-syncope (3.13%), cardiogenic 
shock (4.69%) and total circulatory arrest (0.78%). There were no clinical indicators 
of an obstructed valve in the remaining 56 (43,8%) records. These patients 
presented with a change in effort tolerance (n=38) while the remaining 18 subjects 
were complete asymptomatic; valve obstruction in these cases was detected during 
the routine evaluation at the Department of Cardiology follow-up clinic. 
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Table 6. Clinical features prior to reoperation 
Characteristic Reop=128     % 
NYHA Class   
 I   11   8.59 
 II   45   35.16 
 III   44   34.37 
 IV   26   20.32 
 IV-intubated   2   1.56 
Rhythm   
 Sinus rhythm   98   76.56 
 Atrial fibrillation   22   17.19 
 Atrial flutter   3   2.34 
 Heart block   5   3.91 
Clinical presentation    
 Asymptomatic                                                  18   14.06 
 Pulmonary oedema   44   34.38 
 Change in effort tolerance (NYHA I-III)   38   29.69 
 Acute heart failure   17   13.28 
 Syncope and pre-syncope   4   3.13 
 Total circulatory arrest   1   0.78 
 Cardiogenic shock   6   4.68 
Associated conditions   
 Chest pain   9  
 Sternal wound infection   1  
 Recurrent anaemia   2  
 Infective endocarditis   15  
 Pregnancy   9  
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Signs of prosthetic valve endocarditis were present in 15 cases (11.72%), in whom 
two weeks of IV antibiotics were administered prior to their surgery. Nine subjects 
experienced anginal type chest pain. Nine subjects were pregnant all of whom had 
sub-therapeutic anticoagulation levels with INR<2 (range 0.68-1.9) with valve 
obstruction and received mechanical valves during gestation from 12 to 32 weeks. 
The mean haemoglobin was 11.84g/dl (range 6.6 to 16.8 g/dl); two patients had 
haemolytic anaemia. The serum creatinine was >120 µg/l in 17 patients (13.28%).  
 
 
Table 7: INR levels in patients with obstructed mechanical prostheses  
International Normalized Ratio (INR) N=110 %                         p value 
0-2 68 61.81 
2-4 31 28.19 
>4 11 1                         <0.00001 
Mean INR (SD) 2.36 2.39 
Confidence Level (95.0%)               0.43  
   
 
 
The level of anticoagulation in subjects with malfunctioning mechanical prostheses 
was poor. In almost two thirds of instances with obstructed prostheses levels of 
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anticoagulation achieved were poor (INR<2.0); 28.19% were within the therapeutic 
ranges of 2-4 and 1% >4.0 (p<0.0001) (Table 7). 
Diagnosis of valve dysfunction 
 
In over half the patients, (71/128; 55.47%) valve dysfunction was detected 
transthoracic echocardiography and confirmed fluoroscopically. In the remaining 
patients, the diagnosis was made either at fluoroscopy (11.72%) or on 
echocardiography (32.81%). Echocardiography was performed in 113/128 instances 
prior to redo cardiac valve surgery. The EF was mildly impaired (EF 40-49%) in 
24.78% and severely impaired (EF<40%) in 8 (7.08%) patients. The mean left atrial 
size was 52.28mm and mean pulmonary systolic pressure 45mmHg (range 26-104) 
preoperatively, and fell to 49.4mm and 40 mmHg respectively at the six-week 
follow up visit. 
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Table 8: Comparison of pre and postoperative echocardiographic findings  
Echocardiogram data Preoperative  Postoperative  
EF  N=113  % N=92  % 
>=60 30 26.55 19 20.65 
50-59 47 41.59 41 44.57 
40-49 28 24.78 23 25 
<40 8 7.08 9 9.78 
     
LVEDD (mm)     
   Mean (SD) 49.87 (10.40)  49.42 (12.82)            
   Range 27   - 80  34 -  96  
LVESD (mm)     
    Mean (SD) mm 34.55 (8.20)  32.29 (8. 67)  
    Range (mm) 20-78  22   - 71  
Left atrial size mm     
   Mean (SD) 52.58 (14.95)          49.41(12.90)         
   Range 25 - 120   33-  101  
Aortic root size (mm)     
   Mean (SD) 28.16 (6.31)           29.15 (7.72)       
   Range 14 – 56   18 -56  
PAS (mmHg     
   Mean (SD) 45.08 (13.25)  40.15 (12.13)          
   Range 23-104  21 - 78  
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Surgical procedures  
 
The surgical procedures performed are shown in table 9. Emergency surgery was 
performed in 70/128 reoperations (54%); elective reoperation was performed for 
the remaining 58 events. The most common redo valve operations were performed 
in mitral position (62.5%), followed by the aortic (21.09%) and redo double valve 
replacement (14.06%). Most valve prostheses were replaced with mechanical valves 
(78.90%) and 19.54% had biological cardiac prostheses implanted. Two patients had 
suture repair of the para-annular leaks due to misplacement of the annular sutures 
at the first operation. 
 
Seventeen reoperations were performed and mechanical prostheses implanted in 15 
(13.27%) patients who were HIV infected. Eleven presented with high grade 
dyspnoea (NYHA III-IV) at a mean age 29.5 year. Seven patients were on HAART and 
8 patients were not. Anticoagulation was poorly controlled (INR<2) in 15/17 
(88.24%). Thirteen underwent emergency surgery for stuck mechanical prostheses. 
The operative mortality included one CVA, one peripheral vasculopathy related 
retroviral disease and two had termination of pregnancy due to intra-uterine death; 
the rest made an uneventful recovery.  
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The bioprosthetic valve excised at the redo cardiac prosthetic valve replacement 
comprised 14.29% of the total number of reoperations. Overall the Carpentier-
Edward (mean surgical interval 17.5 years) and Medtronic Hancock (mean surgical 
interval 10.5 years) were the commonest bioprosthetic valves replaced (11.91%). 
(Table 10) The three most common mechanical valves replaced were the CryoLife 
On-X, St. Jude and Carbomedics Sorin which accounted for 30.16%, 29,37% and 
20,64% of the explanted mechanical valves respectively. 
 
The surgical interval to reoperation showed that biological valves had a much 
longer interval to reoperation compared to the mechanical valve which averaged 
between 10-17.5 years to reoperation due to poor anticoagulation. (Fig 5) The 
lowest interval (1 year) to reoperation was with the CryoLife On-X mechanical valve 
and highest was the Bjork-Shiley mechanical (40 years). The St. Jude and the 
Carbomedics Sorin had similar intervals to reoperation (9.5 and 8 years 
respectively). Analysis of the INR showed poor anticoagulation for all three 
explanted valves (Cryolife ON-X, St. Jude and Carbomedics Sorin) with levels of 
INR<2 in almost 60%.  
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Figure 5. Time to reoperation: bioprosthesis had a longer interval to reoperation compared to the 
mechanical prosthesis. 
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Table 9: Operative procedures  
Type of surgery  N=128 % 
  Elective 58 45.31 
  Emergency 70 54.69 
   
New prosthesis implanted  N=126  
  Biological prosthesis  25 19.54 
  Mechanical prosthesis  101 78.90 
   
Surgical Procedure     
  Redo AVR*  27 21.09 
  Redo MVR 80* 62.50 
  Mitral prosthetic repair for leaks 2 1.56 
  Redo tricuspid valve replacement 1 0.78 
  Redo DVR 18** 14.06 
 
*Three subjects underwent additional procedures: tricuspid annuloplasty (1), CABG (1) and repair of 
aortic false aneurysm 91). ** Five subjects underwent additional procedures: Subaortic membrane 
resection (1), CABG (1) and aortic root enlargement (3).   
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Table 10: Valve type and years in surgical interval to redo cardiac valve surgery 
Explanted Valve  
 
N=126    Reoperation (%) 
 
Time (*p50) to 
reoperation (yr) 
 Bioprosthesis (18)                                 14.29%  
   Glycar bioprosthesis  1 0.79 8 
   Carpentier-Edwards  7 5.56 17.5 
   Medtronic Hancock  8 6.35 10.5 
   Homograft  1 0.79 35 
   Edward Perimount  1 0.79 
 
2 
 Mechanical (108)  85.71%  
   Carbomedics Sorin  26 20.64 8 
   St. Jude  37 29.37 9.5 
   Cryolife On-X  38 30.16 1 
   Medtronic Hall  3 2.38 2 
   Medtronic Advantage  1 0.79 5 
   Bjork-Shiley  1 0.79 40 
   Medtronic ATS  2 1.59 2.67 
 
*p50= median years of surgical interval to reoperation p =0.0027 
 
The diagnosis of an obstructed mechanical valve was confirmed at operation and 
the mechanism of obstruction identified intraoperatively (table 12). In the Cryolife 
ON-X group 30/38 patients had a thrombosed valve with a median surgical interval 
of one year whereas the St. Jude group had 11/37 patients with median surgical 
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interval of 9.5 years and Carbomedics Sorin group had 13/26 patients with median 
surgical interval of 8 years (table 10). The St. Jude and Carbomedics Sorin groups 
both had higher median surgical interval since valve deterioration had a more 
insidious progression due to pannus ingrowth (see below).  
Table 11: Characteristic of three major mechanical cardiac prosthesis valve explanted 
 ON-X 
(n=38) 
% St. Jude 
(n=37) 
% Sorin 
(n=26) 
   % 
INR Level       
INR <2 24 63.16 22 59.46 16 61.54 
INR>2 14 36.84 15 40.54 8 38.46 
       
Valve pathology       
Thrombosed valve (clot + 
organized thrombus) 
30 78.95 11 29.73 13 50.00 
Pannus ingrowth 1 2.63 14 37.84 7 26.92 
Mixed (pannus+thrombus) 1 2.63 5 13.51 6 23.08 
Prosthetic endocarditis 2 5.26 4 10.81 0 0 
Paraprosthetic leaks 4 10.53 3 8.11 0 0 
 
 
Operative findings 
 
The mechanistic aetiology of valve dysfunction is described in table 12. Obstruction 
by blood clot affecting a single leaflet or both leaflets of mechanical prostheses was 
the predominant finding (75/128) and categorised as fresh clot (34/128), organized 
71 
 
thrombus and mixture of pannus (20/128), fresh clot and organized thrombus 
(21/128). Isolated pannus in-growth causing single mechanical leaflet dysfunction 
(19/128) and infective endocarditis (annular dehiscence, vegetations and para-
prosthetic leaks and root abscess) (13/128) were the other two causes of 
mechanical valve dysfunction. In those who had biological prosthetic valves the 
main findings were leaflet perforation, calcification and para-valvular leaks. In two 
cases misplacement of the annular suture resulted in a para-valvular leak. 
Table 12: Operative findings 
Mechanical prosthesis N=128 % 
  Obstruction of single leaflet with fresh clots 25 19.53 
  Obstruction of single leaflet with organized thrombus 15 11.72 
  Obstruction of single leaflet with pannus in-growth 19 14.84 
  Obstruction of single leaflet with both fresh clots, organized 
     thrombus and pannus in-growth 
12 9.37 
  Paravalvular leak due to suture placement 2 1.56 
  Obstruction of both leaflets with fresh clots 9 7.03 
  Obstruction of both leaflets with organized thrombus 5 3.91 
  Obstruction of both leaflets with fresh clots, organized 
  thrombus and pannus in-growth 
8 6.25 
  Obstruction of single leaflet with infective endocarditis and 
  para-prosthetic leaks 
3 2.34 
  Aortic root abscess 1 0.78 
  Infective endocarditis with vegetations and para-prosthetic leak 9 7.03 
  Stitch leaks 2 1.56 
Biological Prosthesis   
  Calcified bioprosthesis and perforation of leaflets 1 0.78 
  Calcified bioprosthesis with para-prosthetic leaks 12 9.38 
  Aortic root abscess 1 0.78 
  Annular dehiscence and para-prosthetic leak 4 3.12 
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Operative morbidity and postoperative complications  
 
The mean aortic cross clamp time was 107 minutes (range 36-360 minutes). The 
total duration of bypass time ranged was 158 minutes (range 74-465 minutes). 
Most patients (74%) had Crystalloid St. Thomas II cardioplegic solution to establish 
cardiac electro-mechanical arrest and 32 (25%) had cold blood cardioplegic solution. 
The remaining patient had right atrial exclusion with snaring of both vena cavae 
(without cardioplegic arrest) to replace the tricuspid prosthesis. Systemic corporeal 
cooling was employed as part of the myocardial protection strategy but the deep 
hypothermic cardiac arrest was used in one case with prosthetic infective 
endocarditis and an aortic root false aneurysm requiring repair, as well as 
debridement and reconstruction of the mitral annulus.  
 
Table 13 shows that the number of patients requiring inotropic support. Low dose 
inotropic support was employed in 51.55% of the subjects post operatively and the 
remainder received high dose adrenaline with/without an additional inotrope. Three 
patients with postoperative severe left ventricular dysfunction required support with 
the Intra-Aortic Balloon Pump (IABP); all survived the surgery and were discharged 
home. 
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Table 13: Factors influencing the Operative morbidity 
Duration of aortic cross clamp time (minutes)   
   Mean (SD)  107 (51)          
   Range  36 - 360 
Duration of bypass time (minutes)   
   Mean (SD)   158 (65)          
   Range  74 - 465 
Type of cardioplegia N=128 % 
   No cardioplegia used 1 0.78 
   Blood cardioplegia 32 25.00 
   Crystalloid St. Thomas II solution 95 74.22 
Systemic corporeal cooling (degrees Celsius)   
  Nasal temperature probe   
   Mean (SD)   29.14 (2.81)      
   Range  16.1 -35.8 
  Bladder temperature probe   
   Mean (SD)   29.45 (2.40)        
   Range  18.7 - 35.4 
Postoperative inotropic requirement N=128 % 
     Single agent at low dose (adrenaline <0.2 mic/kg/min, dobutamine   
    <5mic/kg/min and dopamine <5mic/kg/min) 66 51.55 
    Adrenaline at high dose (>0.2mic/kg/min) 30 23.44 
    Adrenaline at low dose with additional agent 5 3.91 
    Adrenaline at high dose with additional agent 7 5.47 
    Adrenaline at high dose with milrinone 20 15.63 
Postoperative Intra-Aortic Balloon pump    
    No 125 97.66 
    Yes 3 2.34 
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Early in-hospital mortality total deaths 
The postoperative mortality was 11.50% (13/113); most deaths occurred in the early 
postoperative phase in the ICU: one patient demised on the surgical table; 11 
demised in intensive care unit and one sudden death occurred in the ward after 33 
days.  Mortality was higher after the second and third reoperations. (Fig 6A and 6B) 
(table 14)  
 
Figure 6A (top) and 6B (below) 
The top Kaplan-Meier “failure estimate” graph showed most of the surgical 
mortality occurred in the early postoperative phase. In the bottom graph early 
mortality was higher after each subsequent reoperation after the first reoperation. 
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The median stay in ICU was 4 days (IQR 3-5) and the mean duration of ward stay 
was 12 days (IQR 9-19.5). (table 14) Of the 12 patients who died early, 8 had cold 
crystalloid cardioplegic solution and the remaining 4 had cold blood cardioplegic 
solution as maintenance fluid for myocardial preservation.   
Table 14:  Postoperative mortality and ICU/ward stay 
Early postoperative death (intra-op to ICU) N=113 % 
Total death 13 11.50 
  1st reoperation (n=94) 7* 6.19 
  2nd–4th reoperation (n=34) 6* 5.31 
  Survivors 100 88.50 
Duration of ICU stay Days  
  Mean (SD) 4.53 (3.34)           
  Median (IQR) 4 (3-5)  
  Range 1 – 25  
Duration of ward stay Days  
  Mean (SD)                                         
  Median (IQR) 
  Range 
16.03 (12.93)     
12 (9-19.5)     
 3 - 95                                               
 
 
Three factors emerged as significant predictors for postoperative death. These were: 
cross clamp time greater than 120 minutes (HR 4.84, p=0.024), bypass time more 
than 3.5 hours (HR 5.58, p=0.024) and the third re-operation (HR 4.26, p=0.022). 
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(table 15) Ejection fraction did not have a significant impact on postoperative 
mortality. 
   Table 15: Factors influencing the surgical outcome 
 
 
 
Postoperatively there were 35/128 complications documented (table 14). The 
commonest postoperative complication was a low cardiac output (LCOS) with/ 
without pulmonary oedema or renal failure. Thirteen of the thirty five patients with 
  Hazard ratio P > ǀ Z ǀ [95% Confidence 
interval] 
 
EF Category     
>50 1.511723 0.621 .2932841     7.792129 
40-49 2.129827 0.383 .3900921     11.62844 
<40 6.22e-15    1.000 0.00 - 
     
Cross clamp time     
<90 minutes 1.01069    0.004     1.003305      1.01813 
91-120 minutes 2.106925 0.414 .3520514 12.60933 
>120 minutes 4.844377 0.022 1.252295 18.73999 
     
Bypass time     
2.5-3.5 hrs  3.51392     0.085      .8397428     14.70407 
>3.5 hrs 5.581668    0.024      1.248538 24.9532 
     
Number of 
previous operation 
    
2 4.268935    0.022      1.235402     14.75131 
3 5.343637      0.045      1.035719     27.56971 
4 1.89e-15    1.000              0          
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LCOS demised (table16) The combined postoperative morbidity and mortality 
totalled 30.97% (35/113). 
 
 
Table 16: Immediate postoperative complications 
Immediate postoperative complications n=113 survived demised 
LCOS * 5 7* 
LCOS, CVA 1 1 
LCOS, CVA, renal failure 2 0 
LCOS, ARDS, renal failure 0 3 
LCOS, pulmonary oedema 4 0 
LCOS, Renal failure 1 0 
LCOS, postoperative bleeding 0 1 
Massive haematemesis 0 1 
Systemic embolism with threatened limb **     2 ** 0 
CVA 1 0 
Intra-uterine death 4 0 
Compartment syndrome due to drip infiltration 1 0 
Emotional instability 1 0 
   
% of total redo cardiac surgery population (n=113) 19.45% 11.50% 
Low Cardiac Output Status (LCOS), Cerebral Vascular Accident (CVA),                                                      
* on-table death due to LCOS; ** systemic embolism associated with retroviral disease 
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Early (6week) follow –up 
At the initial 6 weeks 9 patients did not return to the cardiology clinic follow up, 
yielding a follow-up rate of 91%. Table 17 demonstrates the comparison between 
pre and postoperative NYHA class. Effort tolerance improved from 91.4% (NYHA II-
IV) by one or more classes to 96.23% (NYHA class I-II) postoperatively. One patient 
remained in intractable cardiac failure postoperatively with an EF of 20%. 
Table 17: Pre and Postoperative functional class at 6 weeks follow up (NYHA) 
NYHA class Pre-op  
n=128 
   %   % hospital 
mortality 
Post-op 6     
week n=106 
         % 
I 11 8.59 0 67 63.21 
II 45 35.16 8.89 35 33.02 
III 44 34.37 13.64 3 2.83 
III-IV 28 21.87 10.71 1 0.94 
 
 
 
Long term follow up 
The surviving 100 patients (n=113 -13 deaths) had a total follow-up of 272.1 
patient years over 10 years duration: 53 patients had a complete follow-up (53%), 
29 had incomplete follow-up (range 6 months to 8 years) and 18 patients were lost 
to follow up. Five out of 18 were contacted telephonically and were well. The 
remaining 13 subjects were not contactable. 
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Chapter 5: Discussion 
1. Reoperation rate and early mortality  
This study shows that a 4.9% rate of redo valve surgery for 2618 primary cardiac 
valve operations over a ten year period. There were 128 events of redo cardiac 
valvular prosthetic replacement performed in 113 patients. The international data 
show reoperation rates that range from 12.9-22.48%. Tyers et al. (32) had a 
reoperation rate of 12.9% (708/5499) over 17 years in Canada and Morishita (46) 
reported 16% (231/1405) rate from Japan.  Higher rates were reported by Rizzoli et 
al. (26) (1093/4863 22.48%) over a 25 year duration and by Luciani et al. (28) (316/ 
1508, 20.95%) over a six year duration. A probable explanation for our low redo 
rate is that it does not take into account those patients who did not present to 
hospital in time for redo surgery. We do not have reoperation rates from the two 
South African studies in Johannesburg (35) and Stellenbosch (36) for comparison. 
 
Factors influencing operative mortality in reoperations 
In our study we have shown an 11.5% operative mortality for reoperations which is 
much higher than the 3.8% (11/290) and 30 month follow-up mortality of 9.3% 
reported by Luciani et al. in 2006. (28) Our mortality of 11.50% is in keeping with 
data mentioned from recent studies. It is similar to the 11% mortality  reported by 
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Rizzoli et al. (25) and Tyers et al. (32) and to the 12.3 % reported in a South African 
study by Deviri from Johannesburg. Tang et al. from Toronto General Hospital, 
Canada have also reported an overall hospital mortality rate of 9.4% in 2007 and 
showed a 5.4% mortality in NYHA class I-III, rising to 14% in NYHA IV. (35) Our 
corresponding mortality data was 10% for NYHA class I-III and 10.71% for NYHA IV.  
Similar to the study by Deviri et al. over half of our patients presented with NYHA 
III-IV dyspnoea and this was associated with eight of the 13 deaths in our study. 
Taljaard et al. reported only 4 survivors out of 25 patients who presented with 
NYHA III and IV.(34) Functional class on presenting to hospital at the time of cardiac 
prosthesis dysfunction has been shown to be one of the predictors of postoperative 
mortality. In a Cox proportional hazards model Luciani et al. showed that high 
grade dyspnoea (class NYHA III or IV) was associated with 8.39 fold higher odds 
ratio of death (95% CI 3.44-10.27, p=0.016).(28) Luciani has also shown that poor 
left ventricular function (EF<40%) is a predictor of operative mortality (OR 3.21 95% 
CI 1.48, 7.02, p=0.0079).(28) Although severe left ventricular dysfunction 
(LVEF<0.4) has been identified as one of the predictors for postoperative mortality 
(46) we did not show this in our study, probably because only 7.0% of our subjects 
had markedly depressed left ventricular function. The twelve early in-hospital 
deaths in our study all had an EF>0.4. 
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Although over half of our patients underwent emergency surgery this was not 
associated with increased morbidity or a higher postoperative mortality. The high 
rate of mitral valve redo surgery (62.50%) compared to aortic valve (21.09%) and 
double valve redo operations (14.70%) in our study may in part be explained by the 
high rate of rheumatic valve disease in South Africa with resultant marked atrial 
enlargement compared to degenerative disease in developed countries. 
 
Similar to Tyres et al. we have shown that our mortality is related to number of 
reoperations.(32) This may be related to increasing technical difficulty associated 
with the number of reoperations as well as the clinical condition of the patient at 
presentation.  In our study 15/128 (11.72%) redo valve replacements were 
performed for valve dysfunction due to prosthetic infective endocarditis yielding an 
incidence of cardiac prosthetic endocarditis of approximately 0.013% per patient-
year. Twelve of our patients demised from a LCOS postoperatively and five with 
diagnosis of preoperative prosthetic endocarditis succumbed to early in-hospital 
deaths, yielding a 30.77% (5/13) early in-hospital mortality attributed to infective 
endocarditis. These patients presented with haemodynamic instability, large 
vegetations (>10mm) on the valve, unstable prostheses due to annular dehiscence 
and persistent septicaemia. 
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Cardiac prosthetic endocarditis carries a high mortality rate ranging from 30 to 50% 
preoperatively as well as a three-fold higher postoperative mortality.(14, 19, 20, 52) 
(14, 15, 20, 45, 46) as well as a three-fold higher postoperative mortality. (29, 25) 
Infection of the prosthetic valve acts as a constant source of systemic infection 
which activates the inflammatory pathway continuously, leading eventually to 
prosthetic annular dehiscence with severe regurgitation impairment of myocardial 
contractility.  Reoperative surgery for infective endocarditis is associated with a high 
mortality (24, 25, 35, 40) ranging from 17% -48%.  
 
 
The Clinical profile of patients undergoing redo valve surgery 
The majority (72.6%) of our patients undergoing redo valve surgery were black 
African, he majority of whom were female, non-pregnant and HIV negative. Almost 
two thirds of the patients were under the age of 40 years. None of these subjects 
had a history of diabetes. Most reoperations were performed in subjects with 
mechanical valves implanted for previous native mitral valve disease for which they 
received either mitral or double (aortic+mitral) valve replacement.  
 
83 
 
Nine females were pregnant at the time of redo cardiac surgery. Two patients had 
DVR and 7 patients had MVR and their age ranged from 17 to 30 years. The 
gestational age ranged from 12 to 32/40 weeks. All of the patients had their INR<2 
(ranges 0.68-1.9) which accounted for mechanical valve thrombosis in 8 patients. 
This implies poor obstetric planning and inadequate anticoagulation predisposing 
to mechanical valve thrombosis. The remaining patient had a biological valve 
(Glycar bioprosthesis) implanted at age 28 and she returned at age 36 for 
reoperative valve surgery due to structural valve deterioration of biological 
prosthesis. 
 
Asymptomatic prosthetic dysfunction 
Features suggesting an obstructed valve were present in 34.4% of subjects and 
another 20 % presented either in acute heart failure or in a LCOS. Over 40% of 
presentations had non-acute low grade dyspnoea or no symptoms indicating the 
importance of a high index of suspicion and careful follow of these subjects to 
detect early prosthesis dysfunction. An important finding of this study was the 
finding of asymptomatic valve dysfunction in 18 subjects (16% of reoperations) 
detected at the routine transthoracic echocardiographic evaluation during follow up. 
This is much higher than the 8% reported by Taljaard (34) and by Deviri (30) in a 
study sample and a clinical setting that was similar to ours. Our higher detection 
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rate could be attributed to continued long term surveillance of subjects at our 
tertiary referral centre. Of the 18 asymptomatic patients one had a biological valve 
and 17 patients had mechanical prostheses. Fourteen of the 17 patients had sub-
therapeutic INR levels < 2. Urgent valve replacement surgery was performed in 
5/18 patients and rest underwent elective surgery. Although there was no 
postoperative mortality, operative morbidities included postoperative pulmonary 
oedema (n=2), intra-uterine foetal death (n=1) and LCOS with CVA and renal failure 
(n=1).  
 
Factors predisposing to mechanical Prosthetic valve dysfunction 
Non-structural valve dysfunction was due to the presence of thrombus, tissue in-
growth (pannus) or vegetations ± annular dehiscence arising from prosthetic 
endocarditis. Of these mechanisms, the single most important factor that 
contributed to mechanical valve dysfunction was poor adherence to the 
anticoagulation protocol (in order to maintain therapeutic INR levels) leading to 
mechanical valve thrombosis. In our study almost two thirds of patients with 
mechanical prostheses had INR<2. Inadequate anticoagulation contributed to non-
structural dysfunction of mechanical valves even in patients with pure pannus 
ingrowth as well as in those with prosthetic endocarditis. 
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While control of the INR at therapeutic levels was a critical factor for maintaining 
anticoagulation, several other factors could have increased the tendency to clotting, 
valve dysfunction and thromboembolism in our study. These factors include the 
degree of left atrial enlargement and the presence of AF.  Also, the degree of left 
ventricular dysfunction has now been recognized as an important contributor to 
stasis and possible valve dysfunction.(13, 41-43, 47) Any foreign material such as 
the sewing ring in the cardiac chamber may trigger off the coagulation pathway 
resulting in tissue deposition and endothelialisation of the suture zone. It may be 
argued that native cardiac valve dysfunction is the primary cause of the entire 
process, leading to cardiac chamber enlargement and AF which together with the 
mechanical prosthesis provide the substrate for thrombosis and resultant 
prosthesis dysfunction. All these factors emphasize the role of full anticoagulation 
in these patients to decrease the tendency to thrombus formation. (31, 50, 51)  
 
2. Valve position and pattern of native valve involvement 
Varying patterns of valve involvement have been reported in reoperative surgery.  
Both Tang and Bortolotti have reported a high reoperative rate for bioprosthesis in 
the aortic position, whereas Rizzoli found a high reoperative rate in mitral position 
for both bioprosthesis and mechanical prosthesis.(24, 25, 31, 35) In our study most 
reoperations were performed for dysfunctional mitral (62.5%) compared to aortic 
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(21%) prostheses. Our data are similar to Rizzoli who showed that 52% had mitral 
lesions and 23.2% had aortic regurgitation.(24, 25) The presence of concomitant AF 
in 17% of our subjects could explain the development of thrombus formation in the 
hinge mechanism of the mechanical valve resulting in an obstructed mechanical 
prosthesis. (41-43, 48) Chesebro et al. reported thromboembolisation in more than 
10% of his patients, increasing 18-fold in the presence of concomitant AF.(41) As 
explained earlier chamber enlargement and the ensuing rhythm disturbance could 
contribute to higher thrombogenicity predisposing to mechanical prosthesis 
obstruction. 
 
3. Mechanical vs Biological valves 
The very low rate of rheumatic heart disease in developed countries with better 
access to care and longer lifespan have contributed to a higher usage of biological 
valves which have a more durable lifespan in the older age group. In Tang et al’s 
study 371 out of 507 biological valves explanted were in aortic position and 175 
out of 507 were in mitral position.(35) In contrast, Ruel and co-workers' studied a 
population of 2348 patients undergoing cardiac prosthesis surgery over a 32 year 
duration. They showed a similar rate of reoperation in aortic and mitral position for 
both mechanical (aortic 6.2% vs mitral 5.8%) and biological prosthesis (aortic 40.4% 
vs mitral 42.4%). There was a higher rate of redo surgery in the bioprosthesis 
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compared to mechanical prosthesis group. The mean age for reoperation was 
61.9±13.6 for the aortic and 59.2 ±12.4 years for the mitral position. (22) 
 
In our study, the median age for the mechanical valve was 32 years (mean 31.4 
years 95% CI 28.7-34) and the median for biological group was 54 years (mean 
52.8, 95%CI 44.9-60.6), showing that our redo cardiac valve subjects were much 
younger in keeping with the profile of rheumatic valvular disease in a developing 
country. We have shown varying intervals from previous valve surgery to 
reoperation for the different types of valve prostheses implanted. The biological 
prostheses in our series had a surgical interval to redo surgery ranging between 2 
to 35 years compared to 1-40 years for the mechanical valve. (total median time to 
dysfunction for all prostheses was 5 years). In our study the Carpentier-Edward 
biological valve had a longer surgical interval to reoperation of 17.5 years compared 
to the Edward Perimount which had a two year interval. The mortality for the 
biological prosthesis group was 3/25 (12%) and for the mechanical prosthesis 
10/101 (9.9%), which is very similar. Biological valve structural failure occurred 
more frequently in the age group <65 years (aortic 26% and mitral 44%) compared 
to those over 65 years (aortic 9% and mitral 6%); no mechanical structural failure 
was shown for the mechanical prosthesis in both age groups and for both positions. 
This is quite different from the Veterans Affairs group who showed that the all-
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cause mortality after aortic valve replacement was 13% lower for the mechanical 
compared to bioprosthetic valve. They did not demonstrate this for the mitral 
position.(30, 49) Similarly, Ruel et al. demonstrated a much higher rate of 
reoperation in the bioprosthetic group versus mechanical valve group and this was 
due to structural valve deterioration of the  biological prosthesis. The age group of 
their study population ranged from 46 to 76 years of age. Freedom from all-cause 
reoperation at 10, 15 and 20 years was 96.2, 94.1 and 93.8% for aortic mechanical 
valves, 76.1, 61.4 and 59.6% for aortic bio-prosthetic valves. Similar rates to the 
aortic were shown for the mitral mechanical valves (96.4, 94.8 and 94.2%) and 
mitral bioprosthetic valves (79.8, 63.3 and 57.6%).(22)  
 
In our mechanical prosthesis group, the commonest valve explanted for non-
structural valve failure was Cryolife ON-X mechanical (38/2151) and this were due 
to poor anticoagulation with INR level<2 in 62.18% of cases. Although this 
amounted to 1.8% of the total number of On-X valves implanted during the ten year 
period the time to surgical intervention was one year with the On-X valve compared 
to the St. Jude valve which had a 9.5 year interval to reoperation. The mechanical 
prosthesis group had high rate of poorly controlled levels of anticoagulation (INR<2) 
at 68/110 (61.81%), the mean INR of the group being 2.36 compared to the 
reference INR≥2 (95% CI 1.93-2.79, p<0.0001). The diagnosis of a thrombosed 
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mechanical valve was identified intraoperatively in 78.95% of patients with the 
Cryolife ON-X valve, 50% of the Carbomedics Sorin and 30% of the St. Jude valves. 
The latter valves had a 9.5 year and 8 year interval to reoperation in keeping with 
pannus ingrowth leading to non-structural dysfunction of the valve. The pathology 
described by the operating surgeon revealed the mechanism of prosthesis failure. 
Obstruction of single mechanical prosthetic leaflet regardless the aetiology made 
up 56.25% of all the reoperations. The combination of a short surgical interval to 
reoperation, coupled with low levels of anticoagulation and fresh clot on the 
explanted valve suggest that Cryolife On-X mechanical valves may require a higher 
level of anticoagulation to prevent the valve thromboses in our study population. 
 
Whereas no structural valve deterioration was identified in the mechanical valve 
group, our study has documented structural valve deterioration of the biological 
prostheses, accounting for 11.72% of the reoperations. Surgical findings revealed 
calcification and/or stiffening; leaflet perforation with/without paravalvular leaks 
and root abscess were found in subjects with infective endocarditis. Two patients 
developed marked calcification of their bioprostheses. The first was a young patient 
who received the Edward Perimount pericardial valve at age of 16 and returned two 
year later for a redo cardiac prosthetic replacement due to calcification of the 
bioprosthetic leaflets. The second patient aged 36 years returned 8 years later with 
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severe calcification of the leaflets and paraprosthetic leaks. Such rapid structural 
valve deterioration has been well described in biological valves implanted in 
younger age groups (14, 19, 22, 23) and for this reason younger patients receive 
mechanical valves. 
 
4. Other Factors influencing postoperative outcome 
Emergency reoperative cardiac valve surgery 
In our study over half the subjects with valve dysfunction underwent emergency 
surgery with an overall early in-hospital mortality rate of 11.50% (13/113) 
compared to no deaths in asymptomatic subjects undergoing elective surgery. The 
urgency of surgery was related to the mechanism of valve dysfunction and the 
severity of presenting symptoms.  Acute obstruction of a mechanical prosthesis 
resulted in an acute presentation with high level dyspnea with/without pulmonary 
oedema and/or cardiogenic shock necessitating emergency surgery. Our 10.71% 
mortality for patients presenting with NYHA IV symptoms (cf 17.5% reported by 
Deviri et al.) suggests that emergency surgery for acute mechanical valve 
obstruction was associated with a lower surgical mortality and morbidity. Deviri 
concluded that early surgery in patient with acute symptoms is associated with a 
better outcome.(35)  
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Compared to elective valve operations emergency surgery is associated with 
increased morbidity and mortality.(18, 25, 32, 40, 49) In a multivariate analysis 
Rizzoli et al. showed that emergent and urgent surgery was associated with a 
hazard ratio of 5.8 and 2.1, respectively.(24) Similarly, Tang et al. examined 743 
patients who underwent reoperative surgery in Toronto and showed that the 
urgency of the operation was an independent predictor of hospital death after redo 
mitral valve surgery. Patient who underwent urgent or emergent reoperation carried 
a 3.8-fold increased risk of hospital death with a 19% mortality in urgent and 33% 
mortality in emergent operations.(35)  
Myocardial protection strategy is an important factor that can influence the 
postoperative mortality and morbidity, as well as short and long term survival. (45- 
47) The mean aortic cross clamp time in our study was 107 minutes (range 36-360 
minutes). This is longer than the 90 minute cut-off shown by Morishita et al. to be 
associated with a 98% of one year survival rate and a 96% of 5-years survival rate. 
He showed that cross-clamp time >121 minutes was associated with lower one and 
five year survival rate, respectively. He also showed that the cardiopulmonary 
bypass time less than 150 minutes had 95% of 1-years survival and 81% of 5-years 
survival rate and a  time longer than 211 minutes led to a decrease in both one and 
five year survival rate to 91% and 77% respectively.(46)  In our study the mean 
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bypass time was 158 minutes and aortic cross clamp time was 107 minutes, which 
probably accounted for the favourable response to inotropes since a longer pump 
time is associated with some degree of ventricular dysfunction before the patient’s 
heart is able to maintain a cardiac output.  
Since most of our reoperations were performed using Crystalloid St. Thomas II 
solution, we are unable to comment on whether the choice of cardioplegia used had 
an influence on postoperative outcome. Morishita et al. showed crystalloid vs cold 
blood cardioplegia in patients with redo cardiac prosthetic valve surgery had better 
one year survival rate (89% vs 95%) but this survival difference decreased at 5 years 
(83% vs 85%).(46) There is conflicting evidence as to which type of cardioplegia is 
superior since studies show  a lower incidence of LCOS with blood cardioplegia,(50) 
while other workers show no difference between cold blood or crystalloid 
cardioplegia. (45,50,51)  
 
Limitations of the study  
Being a retrospective, largely descriptive analysis, this study is limited by lack of 
complete datasets and complete records of anticoagulant status. Furthermore, this 
study examines only those patients who were referred by the cardiologist for 
surgical intervention. These were subjects who presented to the referring hospital 
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with symptoms and were referred the cardiac unit, or were detected during their 
annual follow-up at the cardiology clinic. Our data is therefore limited by the lack of 
a centralized cardiac valve replacement registry to adequately follow up patients 
who demised at home or shortly after presenting to their local rural clinic or 
hospital, nor does it include those subjects who arrived in extremis and demised 
without a diagnosis.  This was not measurable due to poor medical resources and 
poor accessibility to care in rural regions. Furthermore, the focus on the large 
communicable disease burden from tuberculosis and HIV infection might have 
compromised subjects who failed to reach the tertiary care due to misdiagnosis of 
the cause for dyspnoea, delay in referral, and lack of formalised anticoagulation 
treatment and monitoring program. 
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Chapter 6:  Conclusion 
In this study we have documented the clinical profile and surgical outcome of 
patients presenting for redo valve surgery over a ten year period to a referral 
tertiary center. The majority of our patients undergoing redo valve surgery were 
young black African women of childbearing age, some of whom were pregnant, who 
had mechanical prostheses that were obstructed in the mitral position.  
 
The mean age for reoperative cardiac valve prosthetic surgery of 35 years is much 
younger compared to the literature. Luciani et al. (28) from Rome, and Ruel et al. 
(22) from Ontario, Canada have both documented the mean age at reoperation of 
about 60 years. Not only were our patients much younger, but a significant 
percentage (13%) had comorbidities such as HIV infection with/without HAART. This 
is a marked increase compared to the single HIV case reported by Taljaard.(34)  
Also the differences during redo surgery compared to previous surgery may be 
related to the higher prevalence of underlying rheumatic valvular disease in our 
African population.  In contrast to western series where the patients were older and 
had more degenerative disease and to other South African studies (Deviri and 
Taljaard) our patients were much younger, and 13% suffered from significant 
comorbidities such as HIV infection with/without HAART. The low subtherapeutic 
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INR  (INR<2) in the majority  of patients supports the Funderburg hypothesis that 
HIV infection activates a chronic inflammatory response that leads to changes in 
vascular function and  damage to endothelial cells, a process that initiates the 
coagulation cascade.(51, 52) More research is needed to determine whether HIV 
infected subjects need higher levels of anticoagulation to prevent future mechanical 
prosthetic valve thrombosis in susceptible subjects. 
 
Worldwide it is well established that mechanical prostheses have a longer durability 
compared to bioprostheses which are prone to structural deterioration.  
Bioprosthetic valve dysfunction develops within 10 years of implantation and 
requires reoperation in at least 50 to 60% of patients after replacement (22). In our 
study we found that bioprosthesis dysfunction over time was due to valve 
deterioration and leaflet calcification and less commonly to tearing and perforation 
of the leaflets from infective endocarditis. Our findings of thickened, calcified 
leaflets within restricted leaflet motion in the biological prostheses has important 
clinical implications since the patients prone to such deterioration are younger and 
these subjects should therefore receive mechanical valves. The interval to 
reoperation ranged from 10 to 17.5 years for the Medtronic Hancock and Carpentier 
Edward pericardial valves. In our study the interval to redo cardiac valve 
replacement was shorter in the mechanical cardiac prosthetic group due to non-
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structural dysfunction commonly caused by obstructed valve leaflet/s as a result of 
inadequate anticoagulation, even in subjects with pure pannus ingrowth.  
 
The three commonest explanted mechanical valve types were the St. Jude medical, 
Carbomedics Sorin and Cryolife On-X. The shortest interval to reoperation was one 
year with the On-X valve. This is a purely observational finding since all three valve 
types were obstructed as a result of inadequate anticoagulation (subtherapeutic INR 
<2.0). One might be tempted to infer that the On-X valve requires higher levels of 
anticoagulation to prevent valve thrombosis but this needs to be shown in a 
prospective study.  
 
Current literature shows that the incidence of left-sided mechanical valve 
obstruction ranges between 0.5 to 6% per patient years. Whereas it is commonly 
caused by the pannus formation of the mechanical valve in the developed world 
(26,27,44), it is due to thrombosis of the mechanical valve due to inadequate 
anticoagulation in developing countries.(2, 3, 53, 54) In our study 50% of our 
mechanical valve dysfunction group was due to leaflet obstruction from fresh clot 
or organized thrombus and about 18% had pannus ingrowth. Of interest was that 
19% had a mixed aetiology for prosthetic dysfunction characterised by fresh clot, 
organized thrombus and pannus ingrowth. The majority of subjects with valve 
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dysfunction had subtherapeutic INRs raising the question of whether pannus 
ingrowth is a consequence of ongoing inadequate or borderline levels of 
anticoagulation.   
 
Although prosthetic dysfunction has been well studied the finding of mechanical 
valve dysfunction with low grade symptoms has not been well documented. A 
significant finding of our study is that we identified a group of 18/128 (14.06%) 
totally asymptomatic patients with prosthetic valve dysfunction (17 mechanical and 
one biological valve) that was detected during echocardiography performed at our 
routine follow up clinic. These patients were identified by an increasing gradient 
across the prosthetic valve and/or leaflet immobility which was easily detected at 
transthoracic echocardiography. This technique has a potential role for distant 
screening of subjects in rural areas who are unable to gain access to the tertiary 
level care. This modality is eminently feasible in a province like KZN where 
noninvasive cardiac imaging is available in at least six secondary level hospitals in 
the province. Echocardiography will also enable evaluation of left ventricular 
function and the pulmonary pressure in these subjects; this technique facilitates 
closer monitoring of patients with significant left ventricular dysfunction which may 
contribute to valve dysfunction as a result of blood stasis within the left ventricle 
and left atrium and predispose to thrombosis around the hinge of the prosthesis.  
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In addition, the province of KwaZulu-Natal has a large communicable and non-
communicable disease burden. The mixture of rheumatic cardiac valvular disease, 
valvular disease associated with retroviral disease and co-existent HIV infection 
with/without HAART poses several challenges in the evaluation of these patients. 
Many of these patients who present with dyspnea are a diagnostic conundrum for 
the medical practitioner who may readily attribute chest symptoms to HIV infection 
when in fact the symptoms may point to valve dysfunction. A low index of suspicion 
for valve dysfunction is required in such circumstances prompting referral for 
evaluation and imaging. Furthermore, the rapidly changing the landscape following 
the HAART roll out program has converted HIV into a chronic infection; such 
patients may benefit from surgery with prolongation of life expectancy. This subset 
of patients in the study may require further investigations and analysis to determine 
the effects of HAART after valve replacement. 
 
These caveats aside, it should be noted that 68% of our reoperations had poor 
levels of anticoagulation control with INR<2 in the mechanical prosthetic group. 
Anticoagulation is the most crucial factor to prevent prosthetic valve thrombosis, 
making adherence to the anticoagulation regime an absolute essential in the 
management of the patient after valve replacement. We need to think an innovative 
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way to create awareness and an understanding of the importance of 
anticoagulation. Such an innovation must be able to overcome the hurdle of the 
space, time and access to health care in some geographically inaccessible regions. 
An example of this is the concept of cloud-based technology where people can gain 
access to information at any time and anywhere. Cellphone technology and the 
network coverage has also improved over time to include smartphone with 
instantaneous access to medical information on the need of valve replacement, type 
of mechanical valves and finally the need of anticoagulation. The patient who stays 
in a remote rural area where he or she does not have adequate access to health care 
service may benefit as long as one has access to a network. This modality may also 
be used to educate the patient as well as provide a service to newly qualified 
medical professionals.  
 
Recommendations 
There is an urgent need to install measures to prevent valve dysfunction and to 
improve the detection rates for valve dysfunction. 
1. The solution to the problem of anticoagulation lies in basic medical 
education prior to discharge from hospital after valve surgery, implementing 
a successful outreach program to rural communities and setting up INR 
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clinics that are accessible for INR regular checks and monitoring of the dose 
of warfarin properly. 
2. Measures to prevent valve dysfunction and to improve the detection rates for 
valve dysfunction include the wide dissemination of knowledge on 
anticoagulation, education of doctors and patients, improved organization of 
care and the institution of checklists, as well as strong policies and 
guidelines on anticoagulation.  
3. Close collaboration between departments of medicine, cardiology and 
cardiothoracic surgery departments, is important not only for rapid triage of 
symptomatic patients, but also for the implementation of an outreach 
program comprising a team comprising of a nurse, physician, cardiologist 
and cardiothoracic surgeon, to provide support to regional as well as rural 
hospitals in each region. Health education presentations by the team, as well 
as clinic visits to review the INR protocols, policy and examination of 
programs monitoring the INR levels will help raise awareness of the 
seriousness of monthly INR checks to maintain therapeutic levels of the INR.    
4. An ongoing prospective study of anticoagulation by such a team, possibly 
funded by industry, would go a long way to incentivise staff to join the team 
to outreach areas and participate in the project to determine the predictors 
of valve dysfunction after surgery. Such a team would also serve as a bridge 
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between the rural hospital and the tertiary hospital, facilitating ease of access 
to tertiary health care.  
5. An important aspect of the cardiac evaluation is the availability of imaging by 
trained technologists at regional centres who may be the first to detect 
asymptomatic valve dysfunction. The concept of technological support has 
already been implemented in KwaZulu-Natal for the last fifteen years by the 
Department of Cardiology but has been poorly supported by the Health 
authorities. Trained cardiac technologists have been placed at regional 
centres throughout KZN but have not been supported with imaging 
equipment. Such skills should be harnessed and technologists retrained on 
the features of new valves and their appearance on imaging so that any 
changes on imaging may be detected early and the patient referred to the 
tertiary centre. Although our finding of a 6.0% rate of redo valve surgery is 
much lower the 12.9% reported by Tyers et al. (32) in Canada, ours is likely 
an underestimate of the true prevalence of valve dysfunction for the logistical 
reasons of early access to secondary and tertiary care in a developing world 
setting. Had the resources that have already been put in place been 
supported by the health authorities many more cases of prosthetic valve 
dysfunction may have been detected early by routine INR monitoring and 
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echocardiography with avoidance of the catastrophes that have already 
occurred.   
 
Conclusion  
This study has documented a high rate of prosthetic valve dysfunction due to 
obstructed mechanical valve prostheses in the mitral position, in young African 
women as a result of inadequate anticoagulation. While about half the patients may 
be detected more easily because of an acute presentation, a substantial number 
have milder or no symptoms and may be suspected only by a change in their 
symptomatology coupled with low levels of anticoagulation. Patients undergoing 
mechanical prosthetic valve replacement in developing world settings therefore 
need careful ongoing surveillance and reinforcement of the importance of regular 
INR monitoring through structured educational programs. Reoperation for valve 
dysfunction is associated with significant morbidity and mortality related to 
technical factors and the preoperative clinical status of the patient.  
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